Clinical trial NCT05275673
Conditions: Non-Small Cell Lung Cancer Squamous Non-small-cell Lung Cancer Squamous Non-Small Cell Neoplasm of Lung NFE2L2 Gene Mutation
Keywords: NSCLC sqNSCLC NFE2L2 Next Generation Sequencing NGS Mutation Relapsed Refractory Squamous NRF2 Lung Cancer
Sponsor: Faeth Therapeutics
Start date: 2022-07-21; Completion date: 2023-01-24
Enrollment: 7 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
This is a multicenter, randomized, open-label Phase 2 study of sapanisertib in biomarker-defined populations of sqNSCLC. Patients with NFE2L2 (the name for gene encoding the protein called NRF2)-mutated or wild-type sqNSCLC should have disease that has progressed on or after at least two prior systemic therapies for metastatic disease including platinum-doublet chemotherapy and a programmed cell death 1 ligand 1 (PD-L1) inhibitor. The study will evaluate sapanisertib monotherapy in patients with relapsed/refractory sqNSCLC as two separate groups: Group A: NFE2L2-mutated sqNSCLC and Group B: NFE2L2-WT sqNSCLC.

Detailed description:
NFE2L2 mutation status for all patients will be identified using local or central next generation sequencing (NGS) testing on archival or fresh tissue or circulating tumor deoxyribonucleic acid (ctDNA), the results of which must be reviewed and approved by the Sponsor prior to enrollment. Each group will be randomized 1:1 to one of two doses/schedules of sapanisertib. Approximately 30 NFE2L2-mutant and 20 NFE2L2-wild type patients will be enrolled. Patients will be treated with sapanisertib until disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), unacceptable toxicity, withdrawal of consent, or death.

Arms: arm 1: sapanisertib 3 mg once daily (QD) arm 2: sapanisertib 2 mg twice daily (BID) arm 3: sapanisertib 3 mg QD arm 4: sapanisertib 2 mg BID
Interventions: intervention 1: sapanisertib
Intervention descriptions: intervention 1: capsules for oral administration

Protocol documents:
Prot_SAP_002.pdf: 
 
 
​
 
 
 
 A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Muted 
and Wild-Type Squamous Non-Small Cell Lung Cancer  
 
NCT 05275673  
 
4 February 2022 
 
Faeth Therapeutics, Inc.  |  701 Tillery St, #12 1010, Austin, TX 78702 
faeththerapeutics.com 


Calithera Biosciences, Inc. 
CLINICAL RESEARCH PROTOCOL 
Study Title: 
A Randomized, Open-Label Phase 2 Study of the 
TORC 1/2 Inhibitor Sapanisertib in 
Relapsed/Refractory NFE2L2 (NRF2)-Mutated and 
Wild-Type (WT) Squamous Non-Small Cell Lung 
Cancer (sqNSCLC) 
Protocol Identifier: 
CX-228-301
Phase: 
2 
Investigational Product: 
Sapanisertib (CB-228) 
Indication: 
Stage IV NFE2L2-mutated and wild-type squamous 
NSCLC 
Sponsor: 
Calithera Biosciences, Inc. 
343 Oyster Point Blvd, Suite 200 
South San Francisco, CA 94080 
Telephone: +1 (650) 870-1000 
Reference Number: 
United States IND 160584 
Sponsor Medical Monitor: 
Original Protocol: 
v1.0 – 21 December 2021 
Amendment 1: 
v2.0 – 26 January 2022 
Amendment 2: 
v.3.0 – 04 February 2022
This study will be conducted according to the principles of Good Clinical Practice as described in 
International Council for Harmonisation guidelines, including the archiving of essential documents. 
Confidentiality Statement 
The information contained in this document and all information provided to you related to sapanisertib 
are the confidential and proprietary information of Calithera Biosciences, Inc. (“Calithera”) and except 
as may be required by federal, state, or local laws or regulations, may not be disclosed to others without 
prior written permission of Calithera.  However, the investigator may disclose such information to 
supervised individuals working on sapanisertib, provided such individuals agree to be bound to maintain 
the confidentiality of such information. 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of Faeth Therapeutics: For non-commer ial us  only a d su j ct o the applicable Terms of Use


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 2 of 103 
CLINICAL STUDY PROTOCOL CX-228-301 
Sponsor Personnel 
Safety Physician and Medical 
Monitor: 
Associate Director, Clinical 
Science 
Director, Clinical Operations 
CLINICAL STUDY PROTOCOL CX-228-301 
Serious Adverse Event (SAE) Reporting Contact 
Contract Research Organization 
Safety Lead 
SAE Reporting Details (to be 
used for submitting the SAE 
forms)  
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of Faeth Therapeutics: For non-commer ial us  only a d su j ct o the applicable Terms of Use


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 3 of 103 
CALITHERA BIOSCIENCES, INC. 
A Randomized, Open-Label Phase 2 Study of the TORC 1/2 Inhibitor Sapanisertib in 
Relapsed/Refractory NFE2L2 (NRF2)-Mutated and Wild-Type (WT) Squamous Non-Small 
Cell Lung Cancer (sqNSCLC) 
Signature of Agreement for Protocol CX-228-301 
I have read this protocol and agree to conduct the study as outlined herein, in accordance 
with Good Clinical Practice and the Declaration of Helsinki, and complying with the 
obligations and requirements of clinical investigators and all other requirements listed 
in 21 CFR Part 312.  I agree to maintain the confidentiality of all information received or 
developed in connection with this protocol. 
Of note, I am aware that any deviations to this protocol associated with the coronavirus 
disease 2019 (COVID-19) pandemic should be reported identifying this association. 
Print Study Site Name 
Study Site Number 
Print Investigator Name 
Investigator Signature 
Date 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of Faeth Therapeutics: For non-commer ial us  only a d su j ct o the applicable Terms of Use


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 4 of 103 
TABLE OF CONTENTS 
TABLE OF CONTENTS ..................................................................................................................................... 4 
LIST OF TABLES ................................................................................................................................................ 6 
LIST OF FIGURES .............................................................................................................................................. 6 
LIST OF ABBREVIATIONS AND TERMS ..................................................................................................... 7 
1 
INTRODUCTION ..................................................................................................................................... 10 
1.1 
Background and Rationale ............................................................................................................... 10 
1.2 
Disease Under Study ................................................................................................................ . ..... 14 
1.3 
Nonclinical and Clinical Experience With Sapanisertib ........................................................ .......... 14 
1.3.1 
Nonclinical Experience ...................................................................................................... 14 
1.3.2 
Clinical Experience ................................................................................... . . .................... 14 
2 
STUDY OBJECTIVES .............................................................................................................................. 16 
3 
INVESTIGATIONAL PLAN.................................................................................................................... 17 
3.1 
Study Design ........................................................................................ ........................................... 17 
3.2 
Duration of Study ............................................................................................................................. 19 
3.3 
Rationale for Dose and Schedule Selection ....................................... .............................................. 19 
3.4 
Rationale for PK Assessments ................................................ .. ...................................................... 21 
3.5 
Rationale for Biomarker Analysis ......................................... .......................................................... 21 
4 
SELECTION OF STUDY POPULATION .............................................................................................. 22 
4.1 
Inclusion Criteria ....................................................... ...................................................................... 22 
4.2 
Exclusion Criteria .................................................. .......................................................................... 23 
5 
ENROLLMENT AND STUDY PROCEDURES .................................................................................... 26 
5.1 
Informed Consent Process ................................................................................................................ 26 
5.2 
Study Periods .................................................................................................................................... 27 
5.2.1 
Screening ......................... .................................................................................................. 27 
5.2.2 
Treatment ........................................................................................................................... 30 
5.2.3 
Treatment Discontinuation ................................................................................................. 31 
5.2.4 
Follow-Up Visits ................................................................................................................ 32 
5.2.5 
End of Study ....................................................................................................................... 33 
6 
STUDY DRUG INFORMATION ............................................................................................................. 34 
6.1 
Sapanisertib .... ............................................................................................................................... 34 
6.2 
Study Drug Administration .............................................................................................................. 34 
6.2.1 
Preparation and Dispensation ............................................................................................. 35 
6.2.2 
Packaging and Labeling ..................................................................................................... 35 
6.2.3 
Storage, Handling, and Accountability .............................................................................. 35 
6.3 
Dose Modification Guidelines .......................................................................................................... 36 
6.3.1 
Criteria for Dose Reduction ............................................................................................... 43 
6.4 
Management of Specific Toxicities .................................................................................................. 43 
6.4.1 
Management of Hyperglycemia ......................................................................................... 43 
6.4.2 
Management of Hyperlipidemia ......................................................................................... 44 
6.4.3 
Management of Oral Mucositis .......................................................................................... 45 
6.4.4 
Management of Rash .......................................................................................................... 45 
6.4.5 
Preventive Measures for Gastrointestinal Toxicity ............................................................ 45 
6.5 
Treatment Compliance ..................................................................................................................... 45 
7 
PRIOR AND CONCOMITANT THERAPY .......................................................................................... 46 
7.1 
Prior Therapy .................................................................................................................................... 46 
7.2 
Concomitant Therapy ....................................................................................................................... 46 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of Faeth Therapeutics: For non-commer ial us  only a d su j ct o the applicable Terms of Use


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 5 of 103 
7.2.1 
Prohibited Concomitant Medications and Procedures ........................................................ 46 
7.2.2 
Acceptable Concomitant Medication ................................................................................. 47 
8 
SAFETY CONSIDERATIONS ................................................................................................................ 49 
8.1 
Special Safety Considerations .......................................................................................................... 49 
8.1.1 
Overdose Management ....................................................................................................... 49 
8.1.2 
Contraception ..................................................................................................................... 49 
8.1.3 
Pregnancy and Nursing ...................................................................................................... 50 
8.2 
Adverse Events:  Definitions, Causality, Severity and Reporting Procedures ............................... . 50 
8.2.1 
Definitions .......................................................................................................................... 50 
8.2.2 
Assessment of Causal Relationship .................................................................................... 54 
8.2.3 
Assessment of Severity (Intensity) ..................................................................................... 55 
8.2.4 
Adverse Event and Serious Adverse Event Reporting .................................. .. ................. 55 
8.2.5 
Serious Adverse Event Reporting .............................................................. ....................... 57 
8.2.6 
Follow-Up of Serious and Nonserious Adverse Events and Other Reportable 
Information ....................................................................................... ................................. 58 
8.2.7 
Pregnancy and Pregnancy Reporting Procedure .......................... .................................... 58 
8.3 
Clinical Laboratory Safety Tests ...................................................................................................... 58 
8.3.1 
Fasting Lipid Profile ......................................................... ................................................ 59 
8.3.2 
Fasting Serum Glucose Monitoring ............................ ...................................................... 59 
8.4 
Electrocardiograms ............................................................... ........................................................... 60 
8.5 
Vital Signs Measurements and Physical Examinations .................................................................... 61 
8.6 
ECOG Performance Status ............................................................................................................... 61 
9 
ASSESSMENT OF EFFICACY, SAFETY, PHARMACOKINETIC, AND OTHER ENDPOINTS 62 
9.1 
Assessment of Efficacy .................................................................................................................... 62 
9.1.1 
Assessments for the Primary and Secondary Efficacy Endpoints ...................................... 62 
9.2 
Assessment of Safety ................................ ....................................................................................... 63 
9.3 
Assessment of Other Endpoints ........................................................................................................ 63 
9.3.1 
Assessment of Pharmacokinetics ....................................................................................... 63 
9.3.2 
Tumor Biopsies .................................................................................................................. 64 
10 
STATISTICAL METHODS AND SAMPLE SIZE DETERMINATION ............................................ 66 
10.1 
Statistical and Analytical Plans ........................................................................................................ 66 
10.2 
Analysis Populations ....................................................................................................................... 66 
10.2.1 
Response Evaluable Population ......................................................................................... 66 
10.2.2 
Intent-to-Treat (ITT) Population ........................................................................................ 66 
10.2.3 
Safety Population ............................................................................................................... 67 
10.3 
Efficacy Analyses ............................................................................................................................. 67 
10.3.1 
Overall Response Rate ....................................................................................................... 67 
10.3.2 
Duration of Response ......................................................................................................... 67 
10.3.3 
Progression Free Survival .................................................................................................. 67 
10.3.4 
Overall Survival ................................................................................................................. 68 
10.4 
Safety Analyses ................................................................................................................................ 68 
10.5 
Determination of Sample Size and Simon’s Two-Stage Design ...................................................... 68 
11 
STUDY COMMITTEES AND COMMUNICATIONS .......................................................................... 70 
11.1 
Independent Radiology Committee .................................................................................................. 70 
11.2 
Study Steering Committee ................................................................................................................ 70 
11.3 
Independent Data Monitoring Committee ........................................................................................ 70 
12 
LABORATORY REQUIREMENTS ....................................................................................................... 71 
13 
INVESTIGATOR AND ADMINISTRATIVE REQUIREMENTS ...................................................... 72 
13.1 
Ethics ................................................................................................................................................ 73 
13.1.1 
Institutional Review Board................................................................................................. 73 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of Faeth Therapeutics: For non-commer ial us  only a d su j ct o the applicable Terms of Use


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 6 of 103 
13.1.2 
Ethical Conduct of the Study ............................................................................................. 73 
13.1.3 
Patient Information and Informed Consent ........................................................................ 74 
13.1.4 
Maintaining Patient Confidentiality ................................................................................... 74 
13.2 
Data Quality Control and Assurance ................................................................................................ 74 
13.2.1 
Data Protection ................................................................................................................... 75 
13.2.2 
Data Management .............................................................................................................. 76 
13.2.3 
Case Report Forms ............................................................................................................. 76 
13.2.4 
Study Monitoring and Audits ............................................................................................. 76 
13.2.5 
Protocol Deviations ............................................................................................................ 77 
13.3 
Investigational Product Accountability ................................................................................ ........... 77 
13.4 
Financial Disclosure ......................................................................................................................... 78 
13.5 
Compensation for Injury and Insurance ....................................................................... . ................ 79 
13.6 
Retention of Records ........................................................................................................................ 79 
13.6.1 
Quality Assurance Audits and Regulatory Agency Inspections ........... ............................. 80 
13.7 
Study Suspension, Termination, and Completion ......................................... .................................. 80 
14 
USE OF STUDY INFORMATION AND PUBLICATION ................................................................... 81 
15 
REFERENCES ........................................................................................................................................... 83 
16 
SPONSOR APPROVAL ........................................................................................................................... 85 
APPENDIX 1: SCHEDULE OF ACTIVITIES ............................................................................................... 86 
APPENDIX 2: RESPONSE CRITERIA IN SOLID TUMORS, VERSION 1.1 (RECIST V1.1) ................ 90 
APPENDIX 3: ECOG SCALE FOR PERFORMANCE STATUS .............................................................. 100 
APPENDIX 4: NEW YORK HEART ASSOCIATION CLASSIFICATION OF CARDIAC DISEASE 101 
APPENDIX 5: DEFINITION OF ELIGIBLE MUTATIONS FOR ENROLLMENT ............................... 102 
LIST OF TABLES 
Table 1: Study Objectives and Endpoints .... . ...................................................................................................... 16 
Table 2:  Dose Reduction Levels for Sapanisertib ............................................................................................... 36 
Table 3: Sapanisertib Dose Modification and Management Guidelines for Treatment-Related Non-
Hematologic Toxicities .................................................................................................................. 37 
Table 4: Sapanisertib Dose Modification Guidelines for Treatment-Related Hematologic Toxicities 
(Neutropenia, Anemia, Thrombocytopenia) .................................................................................. 42 
Table 5: Criteria for Determining Causal Relationship to Study Drug ................................................................. 54 
Table 6:  Criteria for Determining the Severity (Intensity) of an Adverse Event ................................................. 55 
Table 7:  Clinical Laboratory Safety Tests ........................................................................................................... 59 
Table 8:  Collection Schedule for Pharmacokinetic Assessment .......................................................................... 64 
Table 9:  Statistical Power for the Simon’s Two-Stage Design for Overall Response in Group B 
Dose/Schedule Regimens .............................................................................................................. 69 
LIST OF FIGURES 
Figure 1: Outcomes among patients with NFE2L2 and/or KEAP1 mutations stratified by receipt of first-line 
anti-PD-(L)1 therapy: real-world progression-free survival .......................................................... 11 
Figure 2: Selective activity of sapanisertib in NFE2L2-mutated sqNSCLC xenograft model ............................. 12 
Figure 3: Activity of sapanisertib in NFE2L2m, KEAP1m sqNSCLC and KEAP1/KRASm lung 
adenocarcinoma ............................................................................................................................. 13 
Figure 4: Study Schema ........................................................................................................................................ 18 
Figure 5: Exposure vs. tissue pharmacodynamic effect of sapanisertib ............................................................... 20 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of Fa t  T
r p u cs  Fo  n
ommercial u e n y 
d subject o h  a p ic b e Terms of Use


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 7 of 103 
LIST OF ABBREVIATIONS AND TERMS 
Abbreviation 
Definition 
AE 
Adverse event 
ALT 
Alanine aminotransferase 
ANC 
aPTT 
Absolute neutrophil count 
activated partial thromboplastin time  
ASCO 
American Society of Clinical Oncology 
ASCT 
autologous stem cell transplant 
AST 
Aspartate aminotransferase 
AUC 
Area under the curve 
BCRP 
breast cancer resistance protein 
C1D1 
Cycle 1, day 1 is date of first study treatment administration 
CAP 
College of American Pathologists 
CrCl 
Creatinine clearance 
CFR 
Code of Federal Regulations 
CK 
creatine kinase 
Cmax 
maximum observed concentration 
CLIA 
Clinical Laboratory Improvement Amendments 
CNS 
Central nervous system 
COVID-19 
Coronavirus disease 2019 
CPK 
creatine phosphokinase 
CR 
Complete response 
CRO 
contract research organization 
CSR 
clinical study report 
CT 
Computed tomography 
CTCAE 
Common Terminology Criteria for Adverse Events 
ctDNA 
Circulating tumor deoxyribonucleic acid 
CYP, CYP450 
Cytochrome P450 
DDI 
drug-drug interaction 
DOR 
Duration of response 
ECG 
Electrocardiogram 
ECOG 
Eastern Cooperative Oncology Group 
eCRF 
Electronic case report form 
EDC 
Electronic data capture 
EOT 
End of treatment 
FDA 
Food and Drug Administration 
FDG-PET 
[18F]Fluorodeoxyglucose-positron emission tomography 
FFPE 
formalin-fixed, paraffin-embedded 
FIH 
first-in-human 
GCP 
Good Clinical Practice 
G-CSF
granulocyte colony stimulating factor 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of Fa t  T
r p u cs  Fo  n
ommercial u e n y 
d subject o h  a p ic b e Terms of Use


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 8 of 103 
Abbreviation 
Definition 
GI 
gastrointestinal 
GM-CSF 
granulocyte macrophage-colony stimulating factor 
HIV 
human immunodeficiency virus 
HR 
Hazard ratio 
IB 
Investigator’s Brochure 
IC50 
concentration producing 50% inhibition 
ICF 
Informed consent form 
ICH 
International Conference on Harmonisation 
IEC 
independent ethics committee 
IHC 
INR 
immunohistochemical; immunohistochemistry 
international normalized ratio 
IRB 
Institutional review board 
IRC 
independent radiology committee 
ITT 
Intent-to-treat 
IV 
Intravenous, intravenously 
KEAP1 
Kelch-like ECH-associated Protein (gene and protein name) 
MedDRA 
Medical Dictionary for Drug Regulatory Activities 
mITT 
modified intent-to-treat 
MRI 
Magnetic resonance imaging 
MTD 
maximum tolerated dose 
NCCN 
National Comprehensive Cancer Network 
NCI CTCAE 
National Cancer Institute Common Terminology Criteria for Adverse Events  
NFE2L2 
Name for gene encoding the protein called NRF2 
NGS 
Next generation sequencing 
NRF2 
Name for protein encoded by the Nuclear Factor-erythroid 2-related Factor 2 gene 
(NFE2L2). 
NSAID 
Nonsteroidal anti-inflammatory drug 
NSCLC 
Non-small cell lung cancer 
ORR 
Objective response rate 
OS 
Overall survival 
PD 
Progressive disease 
PET 
positron emission tomography 
PFS 
Progression-free survival 
PK 
Pharmacokinetic(s) 
PLT 
platelets 
PO 
per os; by mouth (orally) 
PPI 
Proton pump inhibitors 
PR 
PT 
partial response 
prothrombin time 
QD 
once daily 
QTc 
rate-corrected QT interval (millisec) of electrocardiograph 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of Fa t  T
r p u cs  Fo  n
ommercial u e n y 
d subject o h  a p ic b e Terms of Use


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 9 of 103 
Abbreviation 
Definition 
QTcB 
Bazette corrected QT interval 
QTcF 
Corrected QT interval, Fridericia’s formula 
RBC 
red blood cell 
RECIST v1.1 
Response Evaluation Criteria in Solid Tumors Version 1.1 
ROS 
Reactive Oxygen Species 
RP2D 
Recommended phase 2 dose 
SAE 
Serious Adverse Event 
SAP 
statistical analysis plan 
sqNSCLC 
squamous non-small cell lung cancer 
SSC 
Study Steering Committee 
SUSAR 
suspected unexpected serious adverse reaction 
TEAE 
treatment-emergent adverse events 
TNBC 
TTP 
Triple negative breast cancer 
Time to progression 
ULN 
Upper limit of normal 
US 
United States 
WHO 
World Health Organization 
WT 
Wild Type 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of Fa t  T
r p u cs  Fo  n
ommercial u e n y 
d subject o h  a p ic b e Terms of Use


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 10 of 103 
1 INTRODUCTION 
1.1 
Background and Rationale 
The transcription factor NRF2 is encoded by the gene NFE2L2, which controls the 
expression of antioxidant and detoxification genes (Robertson, 2020).  In many tumor types, 
NFE2L2 is permanently upregulated due to gain-of-function mutations in the N-terminal 
binding region of KEAP1.  Activated NRF2 suppresses reactive oxygen species (ROS) by 
turning on a range of genes associated with antioxidant capability.  The upregulation of 
NFE2L2 is frequently associated with KRAS and with the PI3K/Akt pathway.  Together, 
these changes result in resistance to chemotherapy and radiation therapy.   
Patients with stage IV squamous non-small cell lung cancer (sqNSCLC) account for 25% of 
all NSCLC diagnosed worldwide, amounting to 40,000 new cases annually in the United 
States and 350,000 annually worldwide.  SqNSCLC remains an area of high unmet need, 
particularly with regard to the availability of targeted therapies.  While targeted therapies 
matched to seven oncogenic drivers are available currently for patients with non-squamous 
NSCLC, there is a scarcity of approved targeted therapies tailored to genetically identified 
subsets of patients in sqNSCLC.  As a result, the current standard of care in sqNSCLC across 
the multiple lines of treatment is limited primarily to chemotherapy and immunotherapy with 
PD-(L)1 inhibitors with limited patient selection strategies.  
SqNSCLC is a genetically heterogeneous disease with multiple genetic aberrations that 
promote tumor growth and survival (Hellyer, 2021; Heist, 2012).  Aberrant activation of the 
NRF2 pathway is an early event in NSCLC tumorigenesis.  The NFE2L2 gene (protein name 
NRF2) is the master regulator of the endogenous cellular antioxidant response, inducing 
transcription of multiple genes involved in defense against reactive oxygen species and 
cellular stress.  NFE2L2 activation can accelerate the metabolic inactivation of certain 
antitumor agents and decrease intracellular drug concentrations, promoting tumor resistance 
and growth.  Activation of the NRF2 pathway can occur through gain-of-function mutations 
in NFE2L2 or loss-of-function mutations in KEAP1, the primary negative regulator of NRF2.  
This pathway is the third most commonly mutated in NSCLC and is activated in over 20% of 
both non-squamous and sqNSCLC.  
Multiple reports have shown that NRF2 activation through either NFE2L2 or KEAP1 
mutation is associated with poor survival, and is predictive of resistance to chemotherapy, 
targeted therapy and chemoimmunotherapy in first line and later lines of therapy in non-
squamous NSCLC (Jeong, 2019; Frank, 2018; Arbour, 2018).  A real-world outcomes 
analysis of a cohort of 700 newly diagnosed metastatic sqNSCLC patients showed that 
NFE2L2 mutation also confers poorer prognosis compared to NFE2L2-WT (Figure 1).  
Median PFS with standard of care combination chemo-immunotherapy in newly diagnosed 
patients with KEAP1/NFE2L2 mutations was significantly shorter compared to those with 
WT KEAP1/NFE2L2 (4.5 vs. 6.5 months) (Wu, 2022).  While there is little published data to 
date on clinical outcomes for NFE2L2-mutated sqNSCLC in the second line setting and 
beyond, the relatively poorer prognosis for newly diagnosed NFE2L2/KEAP1 mutant tumors 
likely carries over to later lines of therapy as well. 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of Fa t  T
r p u cs  Fo  n
ommercial u e n y 
d subject o h  a p ic b e Terms of Use


Property of Fa t  T
r p u cs  Fo  n
ommercial u e n y 
d subject o h  a p ic b e Terms of Use


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 12 of 103 
Figure 2: Selective activity of sapanisertib in NFE2L2-mutated sqNSCLC xenograft 
model 
Source: Paik, 2018 
Sapanisertib (MLN0128) shows improved anti-tumor efficacy for tumor volume compared to TORC1 
(everolimus, deforolimus) or TORC1/2 (sapanisertib [MLN0128], AZD2014) inhibitors in an NFE2L2-
mutant sqNSCLC xenograft model. X-axis in days post-implant; y-axis: tumor volume (mm3) 
 
These preclinical data led to a phase 2 clinical trial of sapanisertib in relapsed/refractory 
patients with sqNSCLC harboring NFE2L2 or KEAP1 mutation, and lung adenocarcinoma 
with KEAP1 + KRAS mutations (Paik, 2020).  Patients were heavily pretreated with a 
median of 2 prior lines of systemic therapy including chemotherapy and PD-(L)1 inhibitor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of Fa t  T
r p u cs  Fo  n
ommercial u e n y 
d subject o h  a p ic b e Terms of Use


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 13 of 103 
Figure 3: Activity of sapanisertib in NFE2L2m, KEAP1m sqNSCLC and 
KEAP1/KRASm lung adenocarcinoma 
Source: Paik, 2020 
Spider plot of responses to sapanisertib in a single-arm phase 2 clinical trial.  Figure depicts the trajectory of 
percent change in sum tumor diameter against time from cycle 1 day 1 (C1D1).  NFE2L2-mutant sqNSCLC 
(green), KEAP1-mutant (blue), and KRAS/KEAP1 or NFE2L2 co-mutant NSCLC (red). 
 
Sapanisertib, given at a dose of 3 mg QD, was well-tolerated in this study.  
 
 
 
 
The 3 mg QD dose is below the previously defined maximally 
tolerated dose (MTD) of 6 mg QD and RP2D of 5 mg QD in prior phase 1/2 study.  Based on 
the observed single-agent activity in NFE2L2-mutated sqNSCLC at a lower than RP2D dose, 
further dose refinement is warranted to optimize efficacy and safety in this biomarker-
specific subset of patients with sqNSCLC. 
 
 
  
 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of Fa t  T
r p u cs  Fo  n
ommercial u e n y 
d subject o h  a p ic b e Terms of Use


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 14 of 103 
1.2 
Disease Under Study 
Patients with histologically or cytologically documented metastatic sqNSCLC harboring the 
NFE2L2 mutation or NFE2L2-WT that has progressed on or after platinum-based 
chemotherapy and anti-PD-(L)1 checkpoint inhibitors will receive treatment in this study.  
1.3 
Nonclinical and Clinical Experience With Sapanisertib 
1.3.1  Nonclinical Experience 
Sapanisertib inhibited phosphorylation of downstream modulators of mTORC1and mTORC2 
in human U87 glioblastoma tumor xenograft models in mice and showed strong tumor 
growth inhibition at tolerable oral (PO) doses in all 8 xenograft models tested. 
Sapanisertib was rapidly absorbed after PO administration to mice, rats, dogs, and monkeys, 
with high PO bioavailability.  [14C]-Sapanisertib was rapidly and widely distributed 
throughout the body in Long-Evans rats; radioactivity was eliminated from most tissues at 
48 hours postdose. 
 
  
Sapanisertib distributed mainly to the plasma of human blood.  There was no obvious 
concentration-dependent red blood cell (RBC) distribution of sapanisertib in human blood. 
The nonclinical toxicology profile has been thoroughly characterized in a comprehensive 
toxicology program that included single-dose and 1- and 3-month repeat-dose studies in rats 
and monkeys; in vitro and in vivo genotoxicity studies; range-finding embryo-fetal studies; a 
phototoxicity assay; and a CV safety pharmacology study in monkeys.  The results of these 
studies are generally consistent with pharmacologic inhibition of mTORC1/2 activity and 
have demonstrated an acceptable safety profile for continued evaluation and development of 
sapanisertib in patients with cancer.  See Investigator’s Brochure for additional details of 
non-clinical data. 
1.3.2 Clinical Experience 
 
 
 
 
 
 
 
 
 
 
 
 
Property of Fa t  T
r p u cs  Fo  n
ommercial u e n y 
d subject o h  a p ic b e Terms of Use


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 15 of 103 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Safety data from sapanisertib monotherapy and combination studies are reported in the 
Investigator’s Brochure. 
1.3.2.1 Clinical Pharmacokinetics of Sapanisertib 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of Fa t  T
r p u cs  Fo  n
ommercial u e n y 
d subject o h  a p ic b e Terms of Use


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 16 of 103 
2 STUDY OBJECTIVES 
Table 1: Study Objectives and Endpoints 
Objectives 
Endpoints 
Primary 
To select optimal efficacious dose/schedule, 
evaluate anti-tumor activity, and assess the 
safety of sapanisertib monotherapy in 
patients with metastatic, relapsed/refractory 
NFE2L2-mutant and wild-type sqNSCLC 
• Investigator-assessed ORR per RECIST v1.1 
• Safety measured by type, incidence, severity, seriousness, 
and study drug-relatedness of adverse events per CTCAE 
v5.0 and other safety parameters (eg, lab assessments) 
Secondary 
To evaluate the durability of response to 
sapanisertib in NFE2L2-mutated and wild-
type sqNSCLC 
• Duration of response (DOR) and progression-free 
survival (PFS), per RECIST v1.1 
To evaluate overall survival of patients with 
NFE2L2-mutated and wild-type relapsed/ 
refractory sqNSCLC 
• Time from randomization to death from any cause 
• Overall survival at 6 and 12 months 
Exploratory 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CTCAE v5.0, Common Terminology Criteria for Adverse Events Version 5.0; RECIST v1.1, Response 
Evaluation Criteria in Solid Tumors Version 1.1; sqNSCLC, squamous Non Small Cell Lung Cancer; PD-
(L)1, 
 
 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of Fa t  T
r p u cs  Fo  n
ommercial u e n y 
d subject o h  a p ic b e Terms of Use


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 17 of 103 
3 INVESTIGATIONAL PLAN 
3.1 
Study Design  
This is a multicenter, randomized, open-label Phase 2 study of sapanisertib in biomarker-
defined populations of squamous NSCLC (sqNSCLC).  Patients with NFE2L2-mutated 
or -wild-type sqNSCLC should have disease that has progressed on or after at least two prior 
systemic therapies for metastatic disease including platinum-doublet chemotherapy and a 
PD-(L)1 inhibitor.  
The study will evaluate sapanisertib monotherapy in patients with relapsed/refractory 
sqNSCLC as two separate groups: 
• 
Group A: NFE2L2-mutated sqNSCLC 
• 
Group B: NFE2L2-WT sqNSCLC  
Patients with KEAP1 mutations are permitted in Group B.  NFE2L2 and KEAP1 mutation 
status for all patients will be identified using local or central NGS testing on archival or fresh 
tissue or ctDNA, the results of which must be reviewed and approved by the Sponsor prior to 
enrollment.  Each group will be randomized 1:1 to one of two doses/schedules of 
sapanisertib.   
• 
Cohort 1: Sapanisertib 3 mg QD  
• 
Cohort 2: Sapanisertib 2 mg BID 
Group A will consist of 30 patients with NFE2L2-mutated sqNSCLC randomized 1:1 to one 
of the two sapanisertib doses/schedule cohorts. 
Group B will consist of between 10 and 34 patients with NFE2L2-WT sqNSCLC 
randomized 1:1 into the two sapanisertib dose/schedule cohorts (Cohorts 1 and 2).  For 
Group B only, both dose/schedule cohorts will follow a Simon 2-Stage design, in which 
Stage 1 will enroll 9 response-evaluable patients, and may expand to a total of 17 response-
evaluable patients if 1 or more objective responses are observed in Stage 1. However, if no 
objective response are observed among the first 10 NFE2L2-WT patients enrolled in Group 
B (from Cohorts 1 and 2 combined), the Sponsor reserves the right to discontinue Group B 
enrollment.  
Randomization may continue until approximately 30 response evaluable NFE2L2 mutant 
(Group A) and at least 10 response evaluable NFE2L2-WT patients (Group B) have been 
enrolled. 
Altogether, the study may enroll up to a total of approximately 64 patients across the two 
groups.  Patients who discontinue prior to first on-treatment tumor evaluation will be 
replaced.  Patients will be treated with sapanisertib until disease progression per RECIST 
v1.1 (Appendix 2), unacceptable toxicity, withdrawal of consent, or death.  The primary 
endpoints are a) overall response rate (ORR) per RECIST v1.1 by investigator review and b) 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of Fa t  T
r p u cs  Fo  n
ommercial u e n y 
d subject o h  a p ic b e Terms of Use


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 18 of 103 
safety measured by type, incidence, severity, seriousness, and study drug-relatedness of 
adverse events per CTCAE v5.0 and other safety parameters (eg, aggregate review of 
laboratory assessments).   
Selection of the recommended dose and schedule will be based on aggregate efficacy 
measurements (ORR, DoR, DCR, and PFS), cumulative safety across all patients treated at 
that particular dose/schedule, and PK data.  Safety will be assessed by cumulative incidence 
of adverse events and laboratory abnormalities during the entire treatment duration.  
Evaluation of efficacy and safety will be conducted jointly by the Sponsor and a Study 
Steering Committee (Section 11.2). 
NFE2L2 mutation status must be identified/verified by local or commercial NGS performed 
at a CAP-accredited and/or CLIA-certified laboratory prior to enrollment.  NFE2L2 mutation 
results must be reviewed and approved by the Sponsor study team prior to enrollment.  A 
commercial liquid biopsy NGS assay based on circulating tumor DNA (ctDNA), if requested, 
will be provided and paid for by the study Sponsor.  In order to receive study-provided NGS 
testing, patients must be pre-screened and meet all eligibility criteria.  No prescreening is 
required for non-study-provided NGS testing.  Patients who are randomized on the basis of a 
non-study-provided NGS assay will be asked to provide a pretreatment blood sample for 
possible retrospective testing (although not required for determination of eligibility at 
screening).  
The study will be conducted at approximately 30 sites in the United States.  Approximately 
64 response-evaluable patients may be enrolled in the study.  A study schema is provided in 
Figure 4.  See Appendix 1 for the Schedule of Events. 
Figure 4: Study Schema 
 
R/R: relapsed/refractory 
* Each Group B cohort will initially enroll up to n=9 (Stage 1), and may expand up to n=17 (Stage 2) if 1 or 
more objective responses are observed in Stage 1. 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of Fa t  T
r p u cs  Fo  n
ommercial u e n y 
d subject o h  a p ic b e Terms of Use


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 19 of 103 
3.2 
Duration of Study 
The study enrollment period is anticipated to be approximately 18 months and the total 
duration of the study period is expected to be up to approximately 3 years. 
3.3 
Rationale for Dose and Schedule Selection 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
  
 
  
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of Faet  herapeut cs  For non- omm
al us  only and s bjec  t  t e appl cabl  erms of Use




Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 21 of 103 
 
  
 
 
 
 
 
 
 
3.4 
Rationale for PK Assessments 
Sparse PK sampling is being conducted during this study.  Data will be used to verify 
sapanisertib exposure and as part of future Population PK assessment of the drug. 
3.5 
Rationale for Biomarker Analysis  
This study is an open-label Phase 2 Study of sapanisertib in biomarker-defined populations 
of sqNSCLC patients.  Sapanisertib will be evaluated in patients with NFE2L2-mutated 
sqNSCLC and WT-sqNSCLC as defined below in Section 4.1.  Correlative studies to 
identify predictive biomarkers will be evaluated to identify patients for future treatment. 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of Fa t  T
r p u cs  Fo  n
ommercial u e n y 
d subject o h  a p ic b e Terms of Use


Property of Fa t  T
r p u cs  Fo  n
ommercial u e n y 
d subject o h  a p ic b e Terms of Use


Property of Fa t  T
r p u cs  Fo  n
ommercial u e n y 
d subject o h  a p ic b e Terms of Use


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 24 of 103 
bone lesions).  All acute toxic effects, except toxicities not considered a safety risk 
for the patient at the investigator’s discretion, must be resolved to Grade < 1 per 
NCI CTCAT version 5.0. 
4. Major surgery or other anticancer therapy not previously specified within 4 weeks.  
5. Unable to swallow oral medications or unwilling to perform mucositis prophylaxis 
6. Unable or unwilling to discontinue:  
i. Proton pump inhibitor (PPI) use ≥ 5 days prior to randomization 
ii. Medications or supplements that are known to be strong inhibitors or inducers of 
CYP3A4 and/or CYP1A2 within 5 times the inhibitor half-life (if a reasonable 
half-life estimate is known) or within 7 days (if a reasonable half-life estimate is 
unknown) before the first dose of study drug.  In general, use of these agents is not 
permitted during the study except when an AE must be managed. 
7. Interstitial lung disease or a history of pneumonitis that required oral or intravenous 
glucocorticoid treatment 
8. Any condition including social, psychiatric or medical (including uncontrolled significant 
concurrent illness) that in the opinion of the Investigator could interfere with treatment or 
protocol-related procedures 
9. Patients who are pregnant or lactating 
10. Symptomatic ascites or pleural effusion.  
Exception: Patients who are clinically stable following treatment for these conditions 
(including therapeutic thoraco- or paracentesis) are eligible. 
11. Refractory nausea and vomiting, uncontrolled diarrhea, malabsorption, significant small 
bowel resection or gastric bypass surgery, use of feeding tubes or other situation that may 
preclude adequate absorption of oral study medication. 
12. Infection requiring more than 5 days of parenteral antibiotics, antivirals, or antifungals 
within two weeks prior to randomization.  Anti-infective therapy must be completed at 
least 7 days before randomization. 
13. Patients receiving systemic corticosteroids greater than prednisone 10 mg or equivalent 
(excluding inhalers or low-dose hormone replacement therapy) within the 7 days before 
treatment initiation. 
14. Previous intolerance to mTOR, AKT, or dual PI3K/mTOR inhibitors. 
15. Patients with symptomatic, active/untreated central nervous system metastasis and/or 
leptomeningeal disease are not eligible.  Patients with treated brain metastases must have: 
i. Received definitive treatment with stereotactic radiosurgery (SRS) or surgery to all 
known CNS lesions  
ii. Be at least 4 weeks post-surgical resection of CNS disease before randomization 
iii. Be symptomatically stable and off steroids for at least 7 days before randomization 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 25 of 103 
iv. No new lesions or progressive disease on baseline CNS imaging on contrast-
enhanced MRI before randomization 
v. Patients with asymptomatic, active/untreated CNS metastases or leptomeningeal 
disease are eligible if the treating physician determines that immediate CNS-
specific treatment is not required to stabilize the patient clinically  
16. Significant active cardiovascular disease including: 
i. Myocardial infarction or symptomatic ischemia within 6 months prior to 
randomization 
ii. Congestive heart failure (New York Heart Association class III to IV) 
iii. Uncontrolled hypertension (ie, systolic blood pressure > 180 mm Hg, diastolic 
blood pressure > 95 mm Hg).  Use of anti-hypertensive agents to control 
hypertension before Cycle1 Day 1 is allowed. 
iv. Uncontrolled or clinically significant conduction abnormalities (eg, patients with 
ventricular tachycardia on antiarrhythmics are excluded; patients with 1st degree 
atrioventricular [AV] block or asymptomatic left anterior fascicular block 
[LAFB]/right bundle branch block [RBBB] are eligible) 
v. Baseline prolongation of the rate-corrected QT interval by Fridericia’s formula 
(QTcF) (eg, repeated demonstration of QTcF interval > 480 milliseconds, or 
history of congenital long QT syndrome, or torsades de pointes) 
17. Participants who are known to be HIV-positive, unless assessed to be healthy with a low 
risk of AIDS-related outcomes.  
18. Known active Hepatitis B or C infection 
19. Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or 
for an unknown reason that may alter the absorption of the study drug. 
 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 26 of 103 
5 ENROLLMENT AND STUDY PROCEDURES 
Study enrollment and procedures are summarized in the following subsections.  The timing 
of all study procedures is provided in the schedule of activities (Appendix 1). 
5.1 
Informed Consent Process 
The investigator will provide for the protection of the patients following all applicable Good 
Clinical Practice (GCP) regulations.  These regulations are available upon request from the 
Sponsor.  The ICF must be reviewed and approved by the Sponsor and the Institutional 
Review Board (IRB)/ Independent Ethics Committee (IEC) before the informed consent 
process may begin. 
Before any study-specific screening or study procedures can be performed for any potential 
patient to be enrolled, the patient must be given or must complete the following: 
• 
Be informed of all pertinent aspects of the study and all elements of informed consent 
• 
Be given time to ask questions and time to consider the decision to participate 
• 
Voluntarily agree to participate in the study 
• 
Sign and date an IRB/IEC approved Informed Consent Form 
NOTE: For the purposes of this study, consenting to the study-provided NGS test is 
considered pre-screening. Patients will be considered enrolled after their mutational 
status has been confirmed/approved by the Sponsor and they have signed the main 
study consent. 
Study personnel must obtain documented consent from each potential patient prior to 
entering in a clinical study.  Consent must be documented by obtaining the dated signature of 
both the patient and the person conducting the consent discussion on the consent form.  If 
local law does not allow written consent, then oral consent, attested to by the dated signature 
of an impartial witness (someone not involved with the conduct of the study), is the required 
alternative.  
If the patient is illiterate, an impartial witness must be present during the entire informed 
consent reading and discussion.  Afterward, the patient should sign and date the informed 
consent, if capable.  The impartial witness should also sign and date the informed consent 
along with the individual who read and discussed the informed consent (ie, study staff 
personnel).  If the patient is legally incompetent (ie, a minor or mentally incapacitated), the 
written consent of a parent, legal guardian or legal representative must be obtained.  
Depending on local law or review committee requirements such consent may also need to be 
signed by an impartial witness. 
The information from the consent form should be translated and communicated to the patient 
in a language understandable to the patient.  When the study patient population includes non-
English speaking people, a certified translated consent form will be provided to the patient or 
otherwise following the IRB-approved procedure at the site. 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 27 of 103 
The initial informed consent form and any subsequent revised written informed consent form 
must receive approval and/or favorable opinion by the IRB/IEC in advance of use.  The 
patient or his/her legally acceptable representative should be informed in a timely manner if 
new information becomes available that may be relevant to the patient’s willingness to 
continue participation in the study.  The communication of this information should be 
documented. 
5.2 
Study Periods 
This study consists of the following parts: screening, treatment, EOT, imaging follow-up (if 
applicable), and survival follow-up.   
Procedures (including sample collections, assessments, and treatments) should be performed 
as close to the scheduled time as possible as defined in the schedule of activities 
(Appendix 1), and at the study center where the patient is treated.  Any nonscheduled 
procedures required for urgent evaluation of safety concerns take precedence over all routine 
scheduled procedures.    
5.2.1 
Screening 
The screening period for the main study extends from 28 days prior to randomization to the 
day of randomization.  Screening procedures are listed in the schedule of activities in 
Appendix 1.  Unless otherwise indicated, all screening assessments must be completed within 
28 days of randomization.  Assessments not completed within the appropriate interval must 
be repeated before randomization. 
For the purposes of this study, there will be no day 0. 
5.2.1.1 Study Identification Numbers 
After obtaining informed consent, study site personnel will assign a unique study 
identification (ID) number to a potential study participant.  Patient numbers will not be 
reassigned or reused for any reason.  Patients should be identified to the Sponsor only by 
their assigned study number, year of birth, and sex.  The Investigator must maintain a patient 
master log.                                              
5.2.1.2 Screening Visit Procedures 
To determine eligibility into the study, patients will undergo required screening evaluations 
as outlined in the schedule of activities (Appendix 1).  All previous cancer treatments, 
including systemic therapies, radiation and/or surgical procedures, should be recorded on the 
patients’ electronic case report forms (eCRF).  Patients must meet all inclusion and none of 
the exclusion criteria (Section 4) to be enrolled in this study.  The investigator is responsible 
for reviewing all screening data to confirm patient eligibility and submitting the study 
eligibility form to the Sponsor.  The Sponsor will review the submitted eligibility form; the 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 28 of 103 
investigator must receive approval for enrollment from the Sponsor before 
randomizing the patient to study. 
An IRB/IEC-approved ICF must be signed and dated before any study-specific (ie, non-
standard of care) screening procedures are performed.  Evaluations performed as part of 
routine care prior to informed consent can be utilized for screening evaluation if performed 
within the appropriate window relative to randomization.  All screening assessments must be 
performed within 28 days of randomization with the following exceptions:  ECOG 
performance status and laboratory eligibility must be determined within 10 days prior to 
randomization as outlined in Appendix 1.  NFE2L2 mutation status may be determined at 
any time prior to enrollment; and for females of child-bearing potential only, a serum or 
urine pregnancy test must be negative within 7 days prior to randomization  
Screening activities include, but are not limited to the following: 
• 
Identification of eligible NFE2L2 mutation or NFE2L2-WT by NGS assay any time 
prior to enrollment.  
– Note:  Patients with any mutations in NFE2L2, irrespective of pathogenicity, will 
be excluded from the NFE2L2-WT designation.  However, NFE2L2-WT patients 
harboring KEAP1 mutation(s) may be considered eligible for enrollment in the 
NFE2L2-WT arm (ie, Group B). 
• 
Demographic information including year of birth, sex, race, and ethnic origin  
• 
Medical history including review of disease history, prior cancer treatments, 
procedures, surgeries, and smoking history 
• 
Review of concomitant medications 
• 
ECOG performance status within 10 days of randomization 
• 
Complete physical examination  
• 
Vital sign measurements including height and weight 
• 
Standard 12-lead electrocardiogram (ECG) with corrected QT interval by Fridericia’s 
Formula (QTcF) 
• 
Clinical laboratory evaluation (serum chemistry, hematology, urinalysis, fasting 
glucose, fasting lipid profile, and coagulation) within 10 days of randomization 
(Table 7). 
• 
Collection of whole blood for biomarker analysis (except for patients who were pre-
screened using the study-provided NGS test) 
• 
For females of child-bearing potential only:  Serum or urine pregnancy test must be 
negative within 7 days prior to randomization. 
• 
Radiographic evaluation of tumor burden comprising diagnostic quality CT with 
intravenous contrast or MRI with contrast that is appropriate for RECIST v1.1 
assessment (Appendix 2).  For patients who cannot receive IV CT contrast, a 
non-contrast CT of the chest with contrast enhanced MRI of the abdomen and pelvis 
is preferred over non-contrast CT of the chest, abdomen and pelvis, however the latter 
is acceptable.   
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 29 of 103 
• 
While provision of archival (or fresh) tumor tissue is not required for eligibility, 
tumor tissue is necessary in order to determine NRF2 pathway activation for the 
secondary efficacy endpoints. Every effort should be made to obtain tumor tissue for 
enrolled patients.  
• 
Note: Cycle 1 (C1), Day 1 (D1) (the date study treatments are first administered) 
assessments completed during screening and within 72 hours of C1D1 do not need to 
be repeated on C1D1 
5.2.1.3 
NGS Testing to Determine NFE2L2 Mutation Status 
To be eligible for this study, patients must have NSCLC with a documented pathogenic or 
suspected pathogenic mutation in the NFE2L2 gene (Group A) or confirmed wild type 
(Group B), identified by NGS and approved by the study Sponsor before randomization. 
Patients with any mutations in NFE2L2, irrespective of pathogenicity, will be excluded from 
the NFE2L2-WT designation.  However, NFE2L2-WT patients harboring KEAP1 
mutation(s) may be considered eligible for enrollment in the NFE2L2 WT-arm (ie, Group B).  
The NGS test for study eligibility must be performed by a CAP- and/or CLIA-certified 
laboratory and may be performed using local, institutional or commercial testing.  NGS 
testing may be tissue or liquid (circulating tumor DNA) based.  Upon request, a liquid biopsy 
NGS test will be provided by the study Sponsor without charge to the patient.  In order to 
receive study-provided NGS testing, patients must meet all eligibility criteria (See Section 4).  
All potential qualifying mutations in NFE2L2 must be reviewed and approved by the 
Sponsor as eligible before the patient can be randomized into the study.  NFE2L2 and 
KEAP1 (if available) mutational status with specific mutation(s), if present, will be recorded 
on the appropriate eCRF. 
 
 
 
 
 
 
Other NGS testing:  Patients may meet study eligibility based upon NFE2L2 mutation 
status detected on other NGS tests (not study provided).  Eligible mutations are described in 
Appendix 5.   NFE2L2 mutations defined as a variant of unknown significance (VUS) by a 
pre-existing NGS panel may still be eligible for the study due to vendor-specific differences 
in how variant pathogenicity is determined.  A copy of the local NGS test must be provided 
and eligible mutation confirmed by study Sponsor before approval for randomization.  
Additionally, patients who are randomized on the basis of a nonstudy-provided NGS test will 
be asked to provide a pretreatment blood sample for possible retrospective testing (although 
not employed for determination of eligibility). 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 30 of 103 
5.2.1.4 
Screen Failures 
Patients who sign an informed consent form but are not randomized into the study are 
defined as screen failures.  For all screen failures, the following information will be captured 
in the electronic data capture (EDC) system:   
ID number, patient demographics, eligibility, NSCLC diagnosis history, minimal smoking 
history, NGS test (only for patients who receive the study-provided NGS assay), NGS results 
(only for patients who have nonstudy-provided NGS testing and have a study-eligible 
NFE2L2 mutation or NFE2L2-WT), and serious adverse events (SAEs) for study-related 
procedures, if applicable. 
5.2.1.5 
Method of Treatment Assignment and Randomization 
Patients with NFE2L2-mutated or wild-type sqNSCLC who experienced disease progression 
during or after prior systemic therapy for metastatic disease, which must have included 
platinum-doublet chemotherapy and immune checkpoint inhibitor therapy (anti-PD-(L)1 +/- 
anti-CTLA-4), if approved and available, administered as separate lines of therapy or as 
combination therapy.  
The study will evaluate sapanisertib monotherapy in patients with relapsed/refractory sq 
NSCLC as two separate groups: 
• 
Group A: NFE2L2-mutated sqNSCLC 
• 
Group B: NFE2L2-WT sqNSCLC  
NFE2L2 mutation status for all patients will be identified using central/local NGS testing on 
archival or fresh tissue or ctDNA, the results of which must be reviewed and approved by the 
Sponsor prior to enrollment. Each group will be randomized 1:1 to one of two 
doses/schedules of sapanisertib.   
• 
Cohort 1: Sapanisertib 3 mg QD  
• 
Cohort 2: Sapanisertib 2 mg BID 
The first dose of study treatment (C1D1) should occur within 96 hours of randomization.   
5.2.2 
Treatment 
While the patient is receiving study treatment, the patient’s clinical status will be evaluated at 
each clinic visit to confirm that the patient is suitable for continuing study treatment and to 
make timely decisions regarding the need for interruption, modification, or restarting of study 
treatment.  Dates for study visits should be based relative to C1D1, which is the date that the 
patient receives the first dose of study treatment.  Following C1D1, visits should occur within 
± 5 days of the scheduled visit date (Appendix 1) unless delayed for safety reasons as 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 31 of 103 
determined by the investigator, Sponsor, or designees.  If the study treatment is held due to 
AEs, investigators should perform additional safety assessments as clinically indicated.   
During both the treatment period, radiographic evaluation of tumor burden (eg, diagnostic 
CT with IV contrast or MRI) will be performed every 6 weeks (42 ± 5 days) from C1D1 
onwards.  The imaging schedule should always be relative to C1D1 and should not be 
adjusted for any delays in treatment cycles due to treatment interruptions.  Imaging should 
continue to be performed until progressive disease is identified by the investigator, the start 
of a new anticancer treatment, withdrawal of consent, or death, whichever occurs first.   
Additional assessments during both treatment periods are summarized in Appendix 1. 
5.2.2.1 
Unscheduled Visits 
Unscheduled visits may be performed anytime to assess or follow-up AEs, at the patient’s 
request, or at the investigator’s request.  Any assessments performed at these visits should be 
recorded on the relevant eCRF. 
If an unscheduled visit is necessary to assess toxicity or for suspected disease progression, 
then diagnostic tests may be performed based on investigator assessment as appropriate. 
5.2.3 
Treatment Discontinuation 
5.2.3.1 
Permanent Treatment Discontinuation 
Discontinuation of study treatment only denotes withdrawal from study treatment and does 
not represent withdrawal from the study. 
The reasons a patient may be discontinued from study treatment include, but are not limited 
to, the following: 
• 
Intolerable or unacceptable AEs  
• 
Objective disease progression per RECIST v1.1   
• 
Patient request, including withdrawal of consent by patient 
• 
Investigator decision 
• 
Protocol violation 
• 
Patient noncompliance 
• 
Symptomatic deterioration (of note, symptomatic deterioration is a reason to 
discontinue treatment, but is not the same as objective disease progression and should 
not be used to determine disease progression per RECIST v1.1 criteria). 
• 
Termination of the study by the Sponsor (Section 13.7) 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 32 of 103 
5.2.3.2 
End of Treatment Definition for Individual Patients 
Patients may receive study drug until they experience disease progression, unacceptable 
toxicity, withdrawal of consent, or for any of the other reasons outlined in Section 5.2.3.1.  
After the last dose of sapanisertib, patients will be followed for 28 days to permit further 
detection of any treatment-related AEs, unless patient starts a new anticancer therapy or 
withdraws consent for follow-up prior to the end of the 28-day safety follow-up period. An 
end-of-treatment (EOT) visit must occur within 28 days following the last study treatment 
and before initiation of any new anticancer therapy or regimen.  If the decision to 
permanently discontinue study drug is made after a prolonged dose interruption (> 28 days), 
any study visit after the 28-day interruption period may be considered the EOT visit. 
Regardless of the EOT visit, the investigator must follow up on all AEs and SAEs related to 
study treatment and other reportable information until the events have subsided, returned to 
baseline, the patient has initiated any other anticancer treatment or, in case of permanent 
impairment, until the condition stabilizes.   
 
The End of Treatment for individual patients is not the same as End of Study for individual 
patients (see below). 
 
5.2.4 
Follow-Up Visits 
5.2.4.1 
Imaging Follow-Up 
Patients who discontinue treatment for reasons other than disease progression or death should 
continue to have follow-up visits for tumor imaging per the schedule of activities 
(Appendix 1) until progressive disease (PD), death, initiation of a new anticancer therapy, or 
withdrawal of consent for study follow-up. 
5.2.4.2 
Survival Follow-Up 
After documented disease progression or the start of a new anticancer treatment, the patient 
moves to the survival follow-up phase.  During survival follow-up, patients (or their treating 
physician or designated family member[s]) will be contacted by the investigator’s staff 
approximately every 3 months until death, withdrawal of consent, the end of the study, or for 
a total period of up to 3 years from the patient’s EOT visit whichever occurs first.  Patients 
also will be asked to report any new anticancer therapies started.  Survival follow-up contact 
may occur by phone, email, mail, or, if needed, information may be found in patient or public 
records/databases.   
Updated survival status may be requested by the Sponsor at any time during the course of the 
study.  Upon Sponsor notification, all patients who do not/will not have a scheduled study 
visit or study contact during the Sponsor-defined time period will be contacted for their 
survival status (excluding patients who have a death event previously recorded and patients 
who have withdrawn consent for study participation). 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 33 of 103 
5.2.4.3 
Loss to Follow-Up 
Every reasonable effort should be made to contact any patient apparently lost to follow-up 
during the course of the study to complete study-related assessments, record outstanding 
data, and retrieve study drug. 
Following unsuccessful telephone contact, an effort to contact the patient by mail using a 
method that provides proof of receipt should be attempted.  Alternate contacts are 
permissible if the patient is not reachable (eg, primary care providers, referring physician, 
relatives).  If needed, information may be found in patient or public records/databases.  Such 
efforts should be documented in the patient’s source documents. 
If all efforts fail to establish contact, the patient will be considered lost to follow-up. 
5.2.5 
End of Study 
Patients will be considered as having completed the study if any of the following criteria are 
met: 
• 
Patient completes survival follow up as defined in Section 5.2.4.2 
• 
Patient is deceased and a date of death is available. 
• 
Patient is known to have died; however, the date of death cannot be obtained. 
(Note:  Every effort must be made to obtain the date of death.) 
• 
Patient withdraws consent for any further contact related to this study. 
• 
The study is terminated by the Sponsor (Section 13.7). 
• 
Permanently lost to follow-up as defined in Section 5.2.4.3 
5.2.5.1 
Study Completion Definition  
The final analyses for the safety, PK, and efficacy endpoints and authoring of a clinical study 
report (CSR) will be conducted after all randomized patients have completed the end of study 
as defined in Section 5.2.5 or withdrawn consent for study follow-up.  
 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 34 of 103 
6 STUDY DRUG INFORMATION 
6.1 
Sapanisertib 
Sapanisertib will be supplied as capsules for oral administration.  Sapanisertib is available in 
2 dose strengths—1 mg and 3 mg—each containing 1 mg and 3 mg of the milled formulation 
of sapanisertib, 
 
 
. 
Both dose strengths are formulated into size 2 capsules, and each dose strength is 
differentiated by color, as listed below: 
• 1 mg sapanisertib capsules: white opaque color. 
• 3 mg sapanisertib capsules: Swedish orange opaque color. 
 
6.2 
Study Drug Administration 
All protocol-specific criteria for administration of study drug must be met and documented 
before drug administration.  Study drug will be administered only to eligible patients under 
the supervision of the investigator or identified sub-investigator(s).   
Sapanisertib will be administered according to the assigned dosing schedule (ie, QD or BID 
schedule) in 21-day cycles.  Sapanisertib will be administered at approximately the same 
time(s) on each dosing day.  Patients should be instructed to take the sapanisertib dose with a 
meal.  On study visit days, although patients should arrive in a fasting state, sites may offer a 
light meal or request that patients bring a light meal to their visits to consume after laboratory 
assessments have been completed and before dosing.  Patients should begin consuming the 
meal no more than 30 minutes before taking the sapanisertib dose.  It is recommended that 
each dose of sapanisertib be taken with 8 oz (240 mL) of water.  Patients should be 
encouraged to drink water regularly to remain hydrated. 
If severe emesis or mucositis prevents the patient from taking a sapanisertib dose, that dose 
will be skipped.  If emesis occurs after sapanisertib ingestion, the dose will not be re-
administered, and patients should simply adhere to the dosing schedule and resume dosing at 
the next scheduled time with the prescribed dosage.  Under no circumstance should a patient 
repeat a dose or double-up doses.  A forgotten or missed dose of sapanisertib should be taken 
if it is possible to do so within 4 hours of the scheduled dosing time for patients at the BID 
schedule and within 12 hours for patients at the QD schedule; otherwise, that dose should be 
skipped, and the next dose should be taken as scheduled.  Any skipped dose should be 
considered a missed dose. Patients should be instructed to report to the site any 
skipped/missed doses as well as the frequency of vomiting occurrences associated with study 
drug administration. 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 35 of 103 
6.2.1 
Preparation and Dispensation 
Sapanisertib study drug will be provided in labeled bottles in accordance with all applicable 
regulations.  Sapanisertib will be dispensed with dosing instructions for home use, including 
the requirement that capsules are stored in their original containers and that capsules be 
swallowed whole and not opened, chewed, or manipulated in any way.  Materials provided 
by the Sponsor should be dispensed to patients with clear administration instructions from 
the investigator. 
Sapanisertib is an anticancer drug and, as with other potentially toxic compounds, caution 
should be exercised when handling sapanisertib capsules. 
6.2.2 
Packaging and Labeling 
Sapanisertib will be provided by Calithera and will be handled at the investigative site as 
open-label material.  Sapanisertib will be provided in 30-ct, 60-cc high-density polyethylene 
(HDPE) bottles with polypropylene, child-resistant caps and induction seal. 
Sapanisertib will be packaged and labeled in accordance with all applicable regulations. 
6.2.3 
Storage, Handling, and Accountability 
Upon receipt at the investigative site, contents must be verified promptly and the proper 
contacts notified of any discrepancies or damages as described in the Study Pharmacy 
Manual. Sapanisertib study drug should be stored in the original bottles until use and stored 
at room temperature from 15 to 30C.  All temperature excursions will be reported to the 
Sponsor for assessment and authorization for continued use.  All investigational supplies 
must be stored in a secure area with controlled access and will be stored in original 
packaging. All study drugs should be used before the retest expiry date.  Storage area 
temperature conditions must be monitored and recorded daily.  A daily temperature log will 
also be kept at the study site. 
Because sapanisertib is an investigational agent, it should be handled with due care.  In case 
of contact with broken capsules, raising dust should be avoided during the clean-up 
operation.  The product may be harmful if inhaled, ingested, or absorbed through the skin.  
Gloves and protective clothing should be worn during the clean-up operation.  The area 
should be ventilated and the spill site washed after material pick-up is complete.  The spilled 
material should be disposed of as hazardous medical waste in compliance with federal, state, 
and local regulations. In case of contact with the powder (eg, from a broken capsule), skin 
should be washed immediately with soap and copious amounts of water for at least 15 
minutes.  In case of contact with the eyes, copious amounts of water should be used to flush 
the eyes for at least 15 minutes. Medical personnel should be notified. 
Patients will be given clear dosing instructions from the investigator for home storage and 
administration of sapanisertib capsules, including the requirement that the capsules must be 
stored in their original containers and that the capsules are to be swallowed whole and not 
chewed or manipulated in any way.  Patients will be instructed to return any unused 
sapanisertib study drug in the original packaging at the appropriate visits. 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 36 of 103 
Please refer to the Study Manual and the Pharmacy Manual for additional instructions. 
6.3 
Dose Modification Guidelines 
Sapanisertib will be administered in continuous 21-day cycles.  Guidelines for sapanisertib 
interruption and reductions for non-hematologic and hematologic adverse events are 
provided in Tables 3 and 4, respectively.  In general, sapanisertib administration should be 
interrupted for treatment-related AEs that are Grade 3 or higher despite supportive treatment 
per standard clinical practice. If there is an interruption of treatment longer than 21 days 
because of insufficient recovery from treatment-related toxicity, the patient may be 
withdrawn from treatment unless there is clinical benefit warranting continuation of 
treatment per discretion of the investigator. In such cases, the decision to resume treatment 
must be first discussed with and approved by the study medical monitor. 
Resumption of treatment should occur at the same dose or a reduced dose depending on the 
severity of the adverse event. The dose reduction steps for sapanisertib for the QD and BID 
dose schedules are shown in Table 2.  If a patient cannot tolerate dose level -2 in either 
schedule, treatment should be permanently discontinued.  Once a patient has had a dose 
reduction, re-escalation to the previous dose is not allowed. 
Table 2:  Dose Reduction Levels for Sapanisertib 
Dose Level 
Cohort 1 (QD) 
Cohort 2 (BID) 
Starting dose 
3 mg QD 
2 mg QAM; 2mg QPM 
Dose level -1 
2 mg QD 
2 mg QAM: 1 mg Q PM 
Dose level -2 
1 mg QD 
1 mg QAM: 1 mg QPM 
 
 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 37 of 103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 38 of 103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 39 of 103 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 40 of 103 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 42 of 103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note:  Events of Grade 3 fatigue do not require study drug interruption. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 43 of 103 
 
  
 
 
 
 
 
 
6.3.1 
Criteria for Dose Reduction 
Sapanisertib administration must be interrupted for treatment-related AEs that are Grade 3 or 
higher despite supportive treatment per standard clinical practice.  If the event resolves to 
Grade 1 (or Grade 2 for rash), as detailed in Tables 3 and 4, or to baseline values within 28 
days of interrupting treatment, the patient may resume study treatment at reduced dose by 1 
dose level (see Tables 3 and 4). For occurrences of severe hyperglycemia, please refer to 
Table 3 for specific dose reduction instructions.  If a patient does not tolerate the lowest dose 
reduction step as shown in Table 2, the patient should permanently discontinue sapanisertib.  
If the investigator feels continuation of therapy at a still further reduced dose may benefit the 
patient, this should be discussed with the study medical monitor and approved at an 
individual patient level. 
All patients who continue to experience any toxicity (hematologic or nonhematologic) of a 
severity that requires more than 2 dose reductions of sapanisertib and continues despite 
administration of appropriate supportive care, study treatment should be discontinued.  
However, if the patient has clear evidence of clinical benefit, consideration may be given to 
continue study treatment with further dose reductions for individual patients, upon review 
and written approval by the Sponsor’s project clinician.  These circumstances should be 
discussed on a case-by-case basis.  As a general rule, if a patient requires dose reduction due 
to study drug-related toxicity, the drug dose may not be re-escalated. 
6.4 
Management of Specific Toxicities 
Detailed sapanisertib dose modification and prevention/prophylaxis guidelines for specific 
clinical events are provided in the following sections.  General guidelines for sapanisertib 
interruption and dose reduction are provided in Section 6.3. 
6.4.1 
Management of Hyperglycemia 
On the basis of the clinical experience in sapanisertib trials, most episodes of hyperglycemia 
observed occurred within the first 60 days after initiation of treatment with sapanisertib, and 
have been mild to moderate in severity, and responsive to oral metformin.  Hyperglycemia has 
not been dose-limiting since the institution of a standard regimen for early treatment of 
hyperglycemia. 
The following preventative measures for hyperglycemia should be followed while on 
treatment with sapanisertib: 
• Follow fasting serum glucose levels during clinic visits. 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 44 of 103 
• Monitor home glucometer test results. 
• Check HbA1c levels approximately every 3 months (4 cycles) during therapy. 
• Recommend lifestyle modifications, as appropriate (balanced diet, limited alcohol 
consumption, increased physical activity). 
• FBG levels  160 mg/dL by glucometer should be followed by closer monitoring of 
serum glucose and possible intervention (See below) 
If any fasting serum glucose reading performed at the site indicates hyperglycemia (> ULN 
or ≥ 110 mg/dL), the study staff should first confirm that the patient was fasting at the time 
of blood specimen collection (ie, nothing by mouth for at least 8 hours before collection).  
All patients developing hyperglycemia during the study should have their glucose closely 
monitored by study staff.   
The investigator should continue close monitoring of patients who develop mild 
hyperglycemia (fasting glucose > ULN ≤ 160 mg/dL). In cases of moderately elevated 
fasting glucose (161-250 mg/dL), therapeutic lifestyle changes should be implemented, and if 
symptomatic, treatment with a fast-acting insulin sensitizer such as metformin should be 
initiated. In these cases, it is recommended to initiate metformin at 500 mg orally (PO) QD, 
and titrate up to a maximum of 1000 mg PO twice daily as needed. Most occurrences of 
symptomatic hyperglycemia in the 161-250 mg/dL range are managed effectively with 
metformin, but early initiation of therapy is recommended to prevent higher grade 
hyperglycemia.   
More aggressive treatment algorithms incorporating other oral hypoglycemic agents (eg, 
sulfonylureas [glipizide or glyburide] and/or DPP-4 inhibitors [sitagliptin or vildagliptin) 
with or without insulin, should be followed for patients with fasting blood glucose >250 
mg/dL, which vary depending on the presence or absence of associated signs or symptoms 
(Table 3). Please refer to the hyperglycemia portion of Table 3 for more specific treatment 
guidelines, which include considerations for patients diagnosed with diabetes mellitus prior 
to study enrollment. The dose of oral hypoglycemic agents should be adjusted in patients 
with renal insufficiency.    
Patients experiencing hyperglycemia should be encouraged to incorporate therapeutic 
lifestyle changes, if appropriate, into their overall medical treatment plan.  Changes may 
include but are not limited to increased physical activity, adherence to a balanced diet, and 
limiting alcohol consumption. If feasible in the clinical context, refer to nutritionist for 
dietary education on diabetic diet and/or diabetes educator for comprehensive diabetic 
education on nonpharmaceutical interventions. 
The investigator should consult an endocrinologist, if needed, to aid in optimizing the 
patient’s hyperglycemia treatment plan. 
6.4.2 
Management of Hyperlipidemia 
Guidance on study drug dose modification for patients with hyperlipidemia is provided in 
Table 3.  Lifestyle modifications, as appropriate (balanced diet, limited consumption of 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 45 of 103 
alcoholic beverages, increased physical activity) should be followed to reduce the chance of 
developing hyperlipidemia on treatment. 
6.4.3 
Management of Oral Mucositis 
Guidance on study drug dose modification for patients with oral mucositis is provided in 
Table 3.  Consider initiation of a nonalcoholic mouthwash or 0.9% saltwater rinses 4 to 6 
times daily with start of therapy before signs of mucositis develop.  Avoid using agents 
containing hydrogen peroxide, iodine, and thyme derivatives in management of stomatitis as 
they may worsen mouth ulcers. 
6.4.4 
Management of Rash 
Patients who develop Grade 4 rash should permanently discontinue study treatment, unless 
they derive clinical benefit, in which case they may be retreated at a reduced dose level after 
recovery to  Grade 1 severity.  Grade 4 rash is defined as rash acneiform/papulopustular 
with papules and/or pustules covering any percentage of body surface area, which may or 
may not be associated with symptoms of pruritus or tenderness, and are associated with 
extensive superinfection, with intravenous antibiotics indicated; life-threatening 
consequences (NCI CTCAE v 5.0). 
6.4.5 
Preventive Measures for Gastrointestinal Toxicity 
Prophylactic use of anti-emetic, antinausea, and antidiarrheal medications is encouraged, and 
these may be administered before each dose of sapanisertib as needed throughout the study. 
6.5 
Treatment Compliance 
On C1D1, patients will be provided with enough sapanisertib capsules to last until their next 
clinic visit.  Patients will return on day 1 of each cycle thereafter and will receive enough 
supply until the next visit.  The number of sapanisertib capsules remaining from the previous 
visit will be counted and recorded. 
The investigator or designee must maintain an accurate record of dispensing the study drug in 
a Drug Accountability Log, a copy of which must be given to the Sponsor at the end of the 
study.  The Drug Accountability Log will record the study drugs received, dosages prepared, 
time prepared, doses dispensed, and doses and/or bottles destroyed.  The Drug 
Accountability Log will be reviewed by the field monitor during site visits and at the 
completion of the study. Patients should be instructed to note any missed doses (with reasons 
thereof) during the cycle and report it at each visit. 
If evidence of tampering is observed, notify the Sponsor and return the questionable 
sapanisertib shipment with the appropriate form to the contract distribution center.  Returned, 
partially used, and unused sapanisertib test article may also be destroyed and documented at 
the study site in accordance with approved site/institution standard operating procedures.  If 
the study site does not have an approved standard operating procedure, investigative product 
may be returned to the distribution center for destruction. 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 46 of 103 
7 PRIOR AND CONCOMITANT THERAPY 
7.1 
Prior Therapy 
Prior and concomitant medications and procedures will be reviewed to determine patient 
eligibility (Section 4). 
7.2 
Concomitant Therapy 
Concomitant treatment is permitted if the medication is not expected to interfere with the 
evaluation of safety or efficacy of the study drugs.  Medications or vaccinations specifically 
prohibited in the exclusion criteria and listed in Section 7.2.1 are not allowed during the 
ongoing study.  If a clinical indication is apparent for a patient to need any medication or 
vaccination specifically prohibited during the study, the patient may be discontinued from 
study treatment.  The investigator should discuss any questions regarding the use of 
prohibited drugs with the medical monitor.  The final decision on any supportive therapy or 
vaccination rests with the investigator and/or the patient’s primary physician.  However, the 
decision to continue the patient on study treatment requires the mutual agreement of the 
investigator and medical monitor. 
7.2.1 
Prohibited Concomitant Medications and Procedures 
Patients are prohibited from receiving the following therapies while in the study treatment 
phase: 
• Other investigational agents or mTOR inhibitors. 
• Other anticancer therapies, including but not limited to chemotherapy, 
immunotherapy, radioimmunotherapy, targeted agents, radiation, or surgery (patients 
can have palliative radiation or surgery during the study for preexisting lesions). 
• Systemic corticosteroids (either intravenous [IV] or oral steroids), unless necessary 
for treatment of a sapanisertib-related AE (eg, rash).  Inhalers and low-dose 
glucocorticoids for replacement therapy are allowed and in general should not exceed 
prednisone 10mg or equivalent. 
• Anti-epileptic drugs for patients with a history of treated brain metastasis. 
• Concomitant administration of any PPI is not permitted during the study.  All patients 
are required to stop taking PPIs at least 7 days before receiving the first dose of study 
drug.  Examples of PPIs include omeprazole, esomeprazole, pantoprazole, 
lansoprazole, and rabeprazole. 
• Acid suppression therapy with histamine H2 receptor antagonists (H2RA) may be 
allowed if needed.  Sapanisertib should be taken about 2 hours before or 10 hours 
after H2RA therapy.   Examples of histamine H2 receptor antagonists include 
ranitidine, famotidine, nizatidine, and cimetidine. 
• Administration of neutralizing antacids and calcium preparations is permitted except 
from 4 hours before until 2 hours after study drug administration.  Examples include 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 47 of 103 
aluminum hydroxide (eg, Alternagel, Amphojel), magnesium hydroxide (eg, Milk of 
Magnesia), and calcium carbonate (eg, Alka-Seltzer, Tums).  Anti-gas preparations 
containing the active ingredients above (ie, aluminum hydroxide, magnesium 
hydroxide, calcium carbonate) also have antacid properties and should also not be 
permitted from 4 hours before until 2 hours after study drug administration.  
However, other anti-gas preparations not containing these active ingredients, for 
example those with alpha-galactosidase or simethicone as the sole active ingredient, 
may be taken as needed irrespective of the timing of sapanisertib administration. 
• Concomitant administration of strong inhibitors or inducers of CYP3A4 or CYP1A2 
must be avoided in this study unless being used to manage an AE.  Examples include: 
o Strong CYP3A4 inhibitors: boceprevir, cobicistat, danoprevir, ritonavir, 
elvitegravir, indinavir, itraconazole, ketoconazole, lopinavir, paritaprevir, 
posaconazole, saquinavir, telaprevir, tipranavir, telithromycin, 
troleandomycin, voriconazole, grapefruit juice 
o Strong CYP3A4 inducers: apalutamide, carbamazepine, enzalutamide, 
mitotane, phenytoin, rifampin, St. John’s wort 
o Strong CYP1A2 inhibitors: ciprofloxacin, enoxacin, fluvoxamine 
• Surgical resection of lesions 
• Palliative radiation to target lesions is not allowed.  Palliative (limited 
field/stereotactic radiosurgery [SRS]) for isolated, symptomatic non-target lesions 
and asymptomatic non-target CNS lesions may be performed in the absence of overall 
progressive disease per RECIST v1.1, provided that the specific plan for palliative 
XRT is first discussed with and approved by the study medical monitor. 
• Live vaccines are not permitted within 28 days prior to first dose and while on study 
treatment.  Examples of live vaccines include, but are not limited to, the following: 
measles, mumps, rubella, chicken pox, yellow fever, nasal seasonal flu, nasal H1N1 
flu, rabies, BCG, and typhoid.  Vaccination with SARS-CoV-2 vaccines available via 
Regular or Emergency Use Authorization granted by the FDA is permitted while on 
study treatment and should be appropriately documented in the EDC. 
During the study, if the use of any concomitant treatment becomes necessary (eg, for 
treatment of an AE), the treatment must be recorded on the appropriate eCRF, including the 
reason for treatment, name of the drug, dosage, route, and start and stop dates of 
administration.  
No therapies are prohibited after a patient has permanently discontinued protocol therapy 
(imaging and survival follow-up periods). 
7.2.2 
Acceptable Concomitant Medication 
Prophylactic use of anti-emetic (including ondansetron and granisetron), antinausea, and 
antidiarrheal medications is encouraged, and these may be administered before the first dose 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 48 of 103 
of study drug, as needed throughout the study before each dosing, and as clinically indicated 
per standard practice. 
Concomitant treatment with bisphosphonates is permitted for treatment of osteoporosis or 
management of existing bone metastasis if initiated at least 4 weeks before the first dose of 
study drug.   
Other medications considered necessary for the safety and wellbeing of the patient may be 
administered at the discretion of the investigator.  Any concomitant medications added or 
discontinued during the study should be recorded on the electronic case report form (eCRF). 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 49 of 103 
8 SAFETY CONSIDERATIONS 
Study assessments of safety include AEs, clinical laboratory tests, ECGs, vital sign 
measurements, physical examinations, and ECOG status.   
Adverse events are discussed in detail in the context of patient management, investigational 
drug dose modification, and safety reporting requirements, including special safety 
considerations and follow-up procedures Sections 8.1 and 8.2.  Clinical laboratory safety 
tests are presented in Section 8.3.  The study procedures for ECGs, vital sign measurements, 
physical examinations, and ECOG status provided in Sections 8.4 through 8.6. 
8.1 
Special Safety Considerations 
8.1.1 
Overdose Management 
There is no specific antidote for overdose with sapanisertib.  Patients who experience 
overdose should be closely monitored and general supportive care should be instituted. 
All overdose events are to be reported within 24 hours of awareness by the study site 
according to Section 8.2.4.2, whether or not the event meets adverse event criteria. 
The medical monitor must be informed of any study drug overdoses. 
8.1.2 
Contraception 
Female patients or a male patient with a female partner of childbearing potential (defined as 
females without a hysterectomy and/or a bilateral oophorectomy/salpingo-oophorectomy, 
and not postmenopausal), must agree to avoid becoming pregnant or impregnating a partner, 
respectively, using (or having their partner use) acceptable methods of contraception 
(described below) during heterosexual activity while receiving study drug.  Additionally, as 
sapanisertib is non-genotoxic, all patients of childbearing potential are to use contraception 
methods and males are not to donate sperm during the study through 14 days following the 
last dose of sapanisertib.  
Contraception methods must include one of the following: 
• True abstinence for the patient during the study and for 14 days following the last 
dose of sapanisertib, if this is in line with their preferred and usual lifestyle. 
• Barrier methods of contraception: 
o Male or female condom with or without spermicide, or 
o Occlusive cap (diaphragm or cervical/vault caps) with spermicide 
• Use of at least one of the following by the female patient or female partner of the 
male patient: 
o Hormonal methods of contraception that inhibit ovulation 
o Placement of an intrauterine device (IUD) or intrauterine system (IUS) 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 50 of 103 
Surgically sterilized or postmenopausal female patients (no menses for > 1 year without an 
alternative medical cause) or male patients with surgically sterilized or postmenopausal 
female partners are exempt from these requirements.  Male patients must include a barrier 
method of contraception (preferably male condom) if sexually active to prevent potential 
transfer of drug effects through the semen.   
Females of childbearing potential must have a negative serum pregnancy test or urine 
pregnancy test within 7 days prior to randomization.   
8.1.3 
Pregnancy and Nursing 
Patients should be informed that taking study drug may involve unknown risks to the fetus 
(unborn baby) if pregnancy were to occur during exposure to study drug.  Sapanisertib may 
have adverse effects on a fetus in utero.  Furthermore, it is unknown whether sapanisertib has 
transient adverse effects on the composition of sperm.  In order to participate in the study, 
patients of childbearing potential must adhere to the pregnancy testing and contraceptive 
requirements outlined in Section 8.1.2.  If there is any question that a patient of childbearing 
potential will not reliably comply with the requirements for contraception, that patient should 
not participate in the study. 
It is not known whether the study drugs are excreted in human milk.  Because of the potential 
harm to the infant, patients who are breastfeeding are not eligible for enrollment. 
Procedures for patients who become pregnant on study are described in Section 8.2.7. 
8.2 
Adverse Events:  Definitions, Causality, Severity and Reporting Procedures 
8.2.1 
Definitions 
Definitions are provided in this section for AEs, SAEs, events related to clinical laboratory 
tests, events related to protocol procedures, and other events reportable to the Sponsor.   
AEs, SAEs, and other reportable safety events will be reported by the patient (or, when 
appropriate, by a caregiver, surrogate, or the participant's legally authorized representative).   
The investigator, who is a qualified physician, and any designees are responsible for 
detecting, assessing, documenting, and reporting events that meet the definition of an AE or 
SAE as well as other reportable safety events.  Investigators remain responsible for follow-up 
of AEs, SAEs, and other reportable safety events for outcome. 
8.2.1.1 
Adverse Events  
An AE is any untoward, undesired, or unplanned medical occurrence in a patient 
administered a medicinal product whether or not considered drug related.  Therefore, an AE 
can be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease, temporally associated with the use of an investigational product 
regardless of causality to the investigational product.   
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 51 of 103 
It is the responsibility of the investigator to document all AEs that occur to the patient during 
the study.   
An AE includes, but is not limited to, the following: 
• 
An AE not previously observed in the patient that emerges during the 
protocol-specified AE safety reporting period (Section 8.2.4.2). 
• 
Any clinically significant worsening of a preexisting condition, intercurrent illness, 
drug reaction, or worsening of the indication under investigation. (Note:  Fluctuations 
of pre-existing conditions that are anticipated (including the disease under study or 
indication) that do not represent a clinically significant exacerbation or worsening are 
not considered AEs).   
• 
Complications occurring as a result of protocol-mandated interventions (eg, invasive 
procedure such as biopsies), including events that occur in the period prior to 
receiving the first dose of the study drug and are related to the protocol-mandated 
intervention (eg, pretreatment medication wash-out procedures, biopsies) 
• 
An AE occurring from overdose (as defined in Section 8.1.1) of a test drug, whether 
accidental or intentional 
• 
An AE that has been associated with the discontinuation of the use of a study drug  
8.2.1.2 
Serious Adverse Events 
An SAE is an AE that meets at least one of the following conditions described below that 
occurs at any dose (or after the informed consent is given and prior to dosing if the SAE is 
related to a protocol-mandated procedure) that include the following: 
• 
Results in death (Note:  death is an outcome, not an event).  Any event resulting in 
death during the safety reporting period (Section 8.2.4.2) must be treated as an SAE 
and reported as such.  An event related to a study procedure that occurs after 
informed consent, but prior to dosing that results in death must also be reported as an 
SAE. 
• 
Is life-threatening  
(wherein a patient is at immediate risk of death as the event occurred).  
A life-threatening experience does not include an experience that, had it occurred in a 
more severe form, might have caused death, but rather an experience as it occurred 
that created an immediate risk of death.  For example, hepatitis that resolved without 
evidence of hepatic failure would not be considered life-threatening, even though 
hepatitis of a more severe nature can be fatal.  Similarly, an allergic reaction resulting 
in angioedema of the face would not be life-threatening, even though angioedema of 
the larynx, allergic bronchospasm, or anaphylaxis can be fatal.  
• 
Requires inpatient hospitalization (formal admission to a hospital for medical 
reasons) or prolongation of an existing hospitalization 
• 
Results in a persistent or significant disability (defined as a substantial disruption in a 
person’s ability to conduct normal life functions) or incapacity 
• 
Results in a congenital anomaly or birth defect 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 52 of 103 
• 
Additionally, important medical events that may not result in death, be 
life-threatening, or require hospitalization may be considered SAEs when, based on 
appropriate medical judgment, the events may jeopardize the patient and may require 
medical or surgical intervention to prevent one of the outcomes listed above.  
Examples of such events include allergic bronchospasm requiring intensive treatment 
in an emergency room or at home, blood dyscrasias or convulsions that do not result 
in hospitalization, or development of drug dependency or drug abuse. 
8.2.1.3 
Events Related to Malignant Neoplasm Progression 
Clear progression of neoplasia should not be reported as an AE or SAE (unless the 
investigator considers the progression of underlying neoplasia to be atypical in its nature, 
presentation or severity from the normal course of the disease in a particular patient). 
Findings that are clearly consistent with the expected progression of the underlying cancer 
should not be reported as an adverse event, and hospitalizations due to the progression of 
cancer do not necessarily qualify for an SAE.  In contrast, all deaths including those related 
to progression of disease and sudden and unexplained death should be reported as an SAE.  
However, if the progression of the underlying cancer leads to death, the death should be 
reported as an SAE of “malignant neoplasm progression.”  If there is any uncertainty about a 
finding being due solely to progression of neoplasia, the finding should be reported as an AE 
or SAE as appropriate. 
8.2.1.4 
Events Not Qualifying as a Serious Adverse Event 
The following are not considered SAEs for this study and, therefore, do not need to be 
reported as SAEs: 
• 
Hospitalization in the absence of an AE (Preplanned or elective hospitalizations):  
Hospitalization or prolongation of a hospitalization is a criterion for an AE to be 
serious; however, it is not in itself considered an SAE.  In the absence of an AE, a 
hospitalization or prolongation of a hospitalization should not be reported as an SAE.  
This is the case in the following situations: 
– The hospitalization or prolongation of hospitalization is needed for a procedure 
required by the protocol.  Day or night survey visits for biopsy or surgery required 
by the protocol are not considered serious. 
– The hospitalization or prolongation of hospitalization is part of a routine 
procedure (eg, stent removal after surgery).  This should be recorded in the study 
file. 
– Hospitalization for survey visits or annual physicals.  This should be recorded in 
the study file. 
– In addition, hospitalizations planned before the start of the study, for a preexisting 
condition that has not worsened, do not constitute an SAE.  Visits to the 
emergency room that do not result in hospital admission are not considered 
hospitalizations, but may constitute a medically important event. 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 53 of 103 
• 
Hospitalization of less than 24-hour duration (eg, patient presents to emergency 
department, but is not admitted) 
• 
Events occurring outside of the safety reporting period:  Events that meet the SAE 
criteria (as outlined in Section 8.2.1.2) and occur after informed consent but before 
the first dose of study drug, which are considered unrelated to screening procedures. 
Note:  If there is any doubt about whether an AE constitutes an SAE, the AE is to be 
treated as an SAE. 
8.2.1.5 
Other Events Reportable to the Sponsor Within 24 Hours 
Certain information, although not meeting one of the definitions of an SAE, must be recorded 
and reported within 24 hours of awareness to the Sponsor.  These include the following: 
• 
Overdose (Section 8.1.1).  All overdoses are recorded in the appropriate eCRF with or 
without an AE.  If the AE associated with the overdose is an SAE, an SAE form must 
be submitted. 
• 
Pregnancies with or without an associated AE (Section 8.2.7) 
8.2.1.6 
Clinical Laboratory Results as Adverse Events  
The investigator is responsible to assess the clinical significance of all laboratory values 
collected during the safety reporting period (Section 8.2.4.2).  Any clinically significant 
laboratory results should be entered as medical history or AEs, as appropriate, in the 
appropriate eCRF. 
An abnormal laboratory result that is not already associated with an AE is to be recorded as 
an AE if it meets any of the criteria below: 
• 
Leading to a change in study drug (eg, dose modification, interruption, or permanent 
discontinuation) 
• 
Requiring a change in concomitant therapy (eg, addition of, interruption of, 
discontinuation of, or any other change in a concomitant medication, therapy or 
treatment) 
• 
At the discretion of the investigator should the abnormality be deemed clinically 
significant 
8.2.1.7 
Adverse Events Due to a Protocol Mandated Procedure 
A protocol-related adverse event is an AE occurring during a clinical study that is not related 
to the study drug but is considered by either the investigator or the medical monitor (or 
designee) to be related to the research conditions (ie, related to the fact that a patient is 
participating in the study).  For example, an AE related to a protocol-mandated procedure 
may be an untoward event occurring during a washout period or an event related to a medical 
procedure required by the protocol.  These are recorded in the eCRF as an AE if nonserious, 
and as an SAE if serious (Section 8.2.5). 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 54 of 103 
8.2.1.8. 
Potential Hy’s Law Cases 
Wherever possible, timely confirmation of initial liver-related laboratory abnormalities 
should occur prior to the reporting of a potential drug-induced liver injury event.  All 
occurrences of potential drug-induced liver injury, meeting the below defined criteria must 
be reported as SAEs (Section 8.2.5). 
Potential drug induced liver injury is defined as the following: 
1. ALT or AST elevation > 3 × ULN  
AND 
2. Total bilirubin > 2 × ULN, without initial findings of cholestasis (for example 
without elevated serum alkaline phosphatase) 
AND 
3. No other immediately apparent possible causes of ALT/AST elevation and 
hyperbilirubinemia, including, but not limited to, viral hepatitis, pre-existing chronic 
or acute liver disease, or the administration of other drug(s) known to be hepatotoxic. 
 
8.2.2 
Assessment of Causal Relationship 
Medical judgement should be used in determining the cause of the AE by considering all 
relevant factors such as, but not limited to, the underlying study indication, coexisting 
disease, concomitant medication, relevant history, pattern of the AE, temporal relationship to 
the study drug, and/or dechallenge or rechallenge with the study drug.  Causal assessment 
could either be “related” (encompasses possibly related, probably related, or certainly 
related) or “not related” (encompasses possibly unrelated, probably unrelated, or certainly 
unrelated).  Criteria for determining causal relationship is defined in Table 5. 
Table 5: Criteria for Determining Causal Relationship to Study Drug 
Related to 
Study Drug 
 
• Absence of alternative causes (or difficult to assign to an alternative cause). 
• AE follows a strong or reasonable temporal sequence from administration of 
study drug. 
• AE could not be reasonably explained by the patient’s clinical state, concurrent 
disease, or other concomitant therapy administered to the patient.  
• Occurrence of the AE follows a known response pattern to study drug. 
• The AE is confirmed with a positive rechallenge or supporting laboratory data. 
Not Related to 
Study Drug 
• An AE that is clearly due to extraneous causes (eg, concurrent disease, 
concomitant medications, disease under study, etc.) 
• Occurrence of the AE does not follow a reasonable temporal sequence from 
administration of the study drug. 
• AE does not follow a known pattern of response to study drug. 
• AE does not reappear or worsen when study drug is restarted. 
• An alternative explanation is likely, but not clearly identifiable. 
AE, adverse event. 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 55 of 103 
8.2.3 
Assessment of Severity (Intensity) 
Severity describes the intensity of a specific AE (mild, moderate, or severe).  The particular 
event may be of relatively minor medical significance (such as severe headache).  Severity is 
not the same as “serious,” which is based on patient/event outcome or action criteria.   
Investigators will grade the severity of AEs according to CTCAE v5.0.  For terms not 
specified within the CTCAE, the criteria in Table 6 should be used to determine grade.   
AE severity should be recorded in the appropriate section of the AE eCRF and in the 
patient’s source documents. 
Table 6:  Criteria for Determining the Severity (Intensity) of an Adverse Event 
Grade 
Intensity or Severity 
Clinical Description 
1 
Mild 
Asymptomatic or mild symptoms, clinical or diagnostic 
observations only; intervention not indicated 
2 
Moderate 
Minimal, local, or noninvasive intervention indicated; limiting 
age-appropriate instrumental activities of daily living 
3 
Severe or medically 
significant 
Not immediately life-threatening; hospitalization or prolongation of 
hospitalization indicated; disabling; limiting self-care activities of 
daily living 
4 
Life-threatening  
Life-threatening consequences; urgent intervention indicated 
5 
Death 
Death related to adverse event 
Source:  Common Terminology Criteria for Adverse Events v5.0 
 
8.2.4 
Adverse Event and Serious Adverse Event Reporting 
8.2.4.1 
Documentation, Diagnosis, and Elicitation 
All AEs and SAEs must be recorded on source documents and collected in the appropriate 
eCRF.  All SAEs must be reported immediately (within 24 hours of learning of the event) to 
the Sponsor by submitting the SAE reporting form.  The contact information for reporting of 
SAEs can be found on the SAE reporting form. 
For patients meeting study eligibility criteria, events that occur after the patient signs 
informed consent but prior to initiation of study drug, unless due to a protocol-mandated 
procedure, will be recorded on the Medical History eCRF.  If the event is related to a 
protocol-mandated procedure, it will be recorded on the AE eCRF.  Similarly, any AE that 
occurs after first dose of study drug through 28 days after the last dose of sapanisertib will be 
recorded on the AE eCRF.  Following the safety reporting period, only SAEs deemed related 
to the study drug need to be reported.  If the patient starts a new anticancer therapy prior to 
the end of the safety reporting period, nonserious AEs and SAEs will no longer be collected.  
AEs should be elicited by asking the patient a nonleading question (eg, “Have you 
experienced any new symptoms since we last spoke or since your last visit?” “Have you 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 56 of 103 
experienced any changes in symptoms since your last visit?”).  The existence of an AE may 
be concluded from a spontaneous report of the patient; from the physical examination during 
assessments; or from other tests such as laboratory tests, ECGs, or other protocol-specified 
procedure.  Although AEs should be based on the signs or symptoms detected during the 
physical examination and on clinical evaluation of the patient, a standard medical 
terminology rather than the patient’s own words should be reported as the AE whenever 
feasible.  The investigator, whenever possible, should combine signs and symptoms that 
constitute a single disease entity into a final diagnosis, if appropriate.  As an example, a 
report of rhinorrhea, nasal congestion, and fever may be reported as upper respiratory tract 
infection, if that is a reasonable diagnosis.   
Each AE must be assessed for duration, severity, seriousness, and causal relationship to the 
study drug.  The action taken with the study drug and the outcome of the event must also be 
recorded. 
Any unanticipated problems must be reported by the investigator promptly to the IRB/IEC. 
Guidance for reporting SAEs is provided in Section 8.2.5. 
All patients who experience an AE will be evaluated at appropriate time intervals until the 
event resolves or stabilizes.  At the conclusion of the study, the investigator and medical 
monitor will assess unresolved AEs and determine if additional follow-up is warranted as 
described in Section 8.2.6.   
All AEs, whether or not related to the study drug, must be fully and completely documented 
on the AE eCRF and in the patient’s clinical record.  In addition, any AE resulting in 
permanent treatment discontinuation must be recorded on the treatment discontinuation 
eCRF as well as documented in the patient’s clinical record.  AE terms should include 
a diagnosis or underlying cause, as available, in preference to listing the individual signs and 
symptoms.  If the diagnosis is not known, the investigator should record each sign and 
symptom as an individual AE. 
8.2.4.2 
Adverse Event Collection, Recording, and Reporting 
The safety reporting period is defined as the time from the first dose of study drug through 
28 days after the last dose of sapanisertib. 
Collection and reporting of AE information will begin at the time the patient signs informed 
consent and continue until any of the following occurs: 
1. Screen failure 
2. End of safety reporting period (28 days after the last dose of sapanisertib) 
a. All AEs and SAEs, regardless of causality, will be collected from the first dose of 
study drug through 28 days after the last dose of sapanisertib 
b. Following the safety reporting period, only related SAEs will be collected 
3. Initiation of a new anticancer treatment.   
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 57 of 103 
 
Recording of AEs:  Events that occur after the patient signs the informed consent but prior 
to initiation of study drug, unless due to a protocol-mandated procedure, will be recorded on 
the Medical History eCRF.  If the event is related to a protocol-mandated procedure, it will 
be recorded on the AE eCRF.  For any patient who subsequently meets eligibility criteria and 
proceeds to treatment, any event occurring during screening must be documented on the 
medical history eCRF and in the patient’s clinical record.  All AEs that occur after the first 
dose of any study drug treatment must also be documented on the AE eCRF and in the 
patient’s clinical record.   
8.2.5 
Serious Adverse Event Reporting 
All SAEs regardless of attribution, other reportable information, and follow-up information 
must be reported within 24 hours of learning of the event during the safety reporting period 
(Section 8.2.4.2), according to the procedures below by completing the SAE form and either 
emailing or faxing the form to the SAE Reporting Contact below.  Following the safety 
reporting period, only SAEs considered to be treatment-related will be reported.  It is 
important that the investigator provide an assessment of causality (relationship) of the SAE 
to study drug at the time of the initial report.  Calithera Biosciences (or designee) will 
process and evaluate all SAEs as soon as the reports are received.  The medical monitor 
should also be contacted for any fatal or life-threatening SAE that is considered related to 
study drug. 
Calithera (or designee) is responsible for reporting relevant SAEs to the appropriate 
regulatory authorities and participating investigators, in accordance with FDA regulations 
21 Code of Federal Regulations (CFR) 312.32, International Council for Harmonisation of 
Technical Requirements for Pharmaceuticals for Human Use (ICH) Guidelines, European 
Clinical Trials Directive (Directive 2001/20/EC), and/or local regulatory requirements and 
monitoring the safety profile of the study drug.  To meet this requirement, Calithera (or 
designee) may request additional information from the study sites including, but not limited 
to, hospitalization records.  Any requests for such information should be addressed in a 
timely manner.  Additionally, any SAE considered by an investigator to be related to the 
study drug treatment that is brought to the attention of the investigator at any time outside of 
the time period specified for SAE reporting must be reported immediately using the SAE 
Report Contact form and submitted to the following:  
SAE Reporting Details (to be used for submitting the SAE forms): 
 
  
Reporting of SAEs by the investigator to the IRB or IEC will be done in accordance with the 
standard operation procedures and policies of the IRB/IEC.  Adequate documentation must 
be maintained showing that the IRB/IEC was properly notified.  In accordance with the 
European Commission Clinical Trials Directive (2001/20/EC), the Sponsor or its designee 
will notify the relevant ethics committees in concerned member states of applicable 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 58 of 103 
suspected unexpected serious adverse reactions (SUSARs) as individual notifications or 
through periodic line listings. 
8.2.6 
Follow-Up of Serious and Nonserious Adverse Events and Other Reportable 
Information 
The investigator must follow-up on all serious and nonserious AEs related to study drugs and 
other reportable information until the events have subsided, returned to baseline, the patient 
has initiated another anticancer treatment, or in case of permanent impairment, until the 
condition stabilizes. 
AEs that remain unresolved at the conclusion of the study may continue to be monitored if 
warranted based on clinical assessment by the investigator and medical monitor.  
For AE follow-up, a patient should be contacted by phone and, as appropriate, sent written 
requests for follow-up information if the patient does not come to the clinic for visits as 
specified in the schedule of activities (Appendix 1) or as requested by the investigator. 
8.2.7 
Pregnancy and Pregnancy Reporting Procedure 
Patients who become pregnant on study will be required to immediately discontinue study 
treatment.  A pregnancy is not considered to be an AE or SAE; however, any female patient 
or female partner of a male study patient who becomes pregnant during study participation or 
within 28 days of last dosing must be reported to the Sponsor using the Pregnancy Report 
Form within the same timelines as an SAE. 
The site will contact the patient at least monthly and document the patient or patient partner’s 
status until the pregnancy has been completed or terminated.  A pregnancy will be followed 
through to outcome.  The outcome of the pregnancy will be reported to the Sponsor 
immediately and within 24 hours if the outcome is a serious adverse experience (eg, death, 
abortion, congenital anomaly, or other disabling or life-threatening complication to the 
mother or newborn).  The study investigator will make every effort to obtain permission to 
follow the outcome of the pregnancy and report the condition of the fetus or newborn to the 
Sponsor.  If a male patient impregnates his female partner, the study personnel at the site 
must be informed immediately and the pregnancy reported to the Sponsor and followed as 
described above. 
AEs and SAEs that occur during pregnancy will be assessed and processed according to the 
AE or SAE processes using the appropriate AE or SAE forms. 
8.3 
Clinical Laboratory Safety Tests 
Laboratory evaluations (hematology, serum chemistry, and urinalysis) will be performed 
according to the schedule of study activities (Appendix 1).  The laboratory analytes to be 
tested are summarized in Table 7.  All laboratory assessments will be completed by the site 
local laboratory and results entered in the appropriate eCRF. 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 59 of 103 
Any clinically significant results should be entered as medical history or AEs, depending on 
the time of the results, in the appropriate eCRF. 
Samples will be stored until the specified analyses are completed and then they will be 
destroyed in accordance with standard laboratory practice and applicable local regulations.   
A different clinical laboratory may be used for unscheduled visits or for urgent care.  Such 
laboratory data will not be entered into the study database and these local laboratories will 
not be included on the Form FDA 1572. 
Table 7:  Clinical Laboratory Safety Tests 
Hematology 
Serum Chemistry 
Urinalysis 
Other 
Hematocrit  
Hemoglobin 
Platelet count 
Red blood cell count 
White blood cell count 
with differential 
 
 
Albumin  
Alkaline phosphatase (AP)  
Alanine aminotransferase (ALT) 
Aspartate aminotransferase (AST) 
Bilirubin (total and direct)[1]  
Blood urea nitrogen  
Calcium (total) 
Carbon dioxide or bicarbonate  
Chloride  
Creatinine 
Glucose  
Magnesium 
Phosphate  
Potassium  
Sodium  
Total protein 
Fasting lipid panel (Total 
cholesterol, triglycerides, LDL 
cholesterol, HDL cholesterol) 
Glucose 
Blood 
Ketones 
Leukocyte esterase 
Nitrite 
pH 
Protein 
Specific gravity 
Turbidity & color 
Urobilinogen 
Bilirubin 
 
Microscopic 
evaluation (performed 
at the discretion of the 
investigator) 
 
For women of 
childbearing age only: 
Pregnancy test (serum 
or urine -HCG) 
Coagulation 
PT 
aPTT 
INR 
Fibrinogen 
[1] Direct bilirubin is only required if total bilirubin is above the upper limit of normal. 
 
8.3.1 
Fasting Lipid Profile 
Prospective monitoring for hyperlipidemia will be managed through fasting lipid testing at 
the time points specified in the Schedule of Activities (Appendix 1).  Patients are required to 
fast overnight (nothing except water and prescribed medications after midnight or for a 
minimum of 8 hours) for each of these measurements.   
8.3.2 
Fasting Serum Glucose Monitoring 
Fasting serum glucose will be measured in the study site at the time points specified in the 
Schedule of Activities (Appendix 1) before administration of sapanisertib, and at other times 
at the discretion of the investigator. Patients are required to fast overnight (nothing except 
water and prescribed medications after midnight or for a minimum of 8 hours) for each of 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 60 of 103 
these measurements.  In-home glucose monitoring is not required on days when fasting 
glucose is measured in the study site. 
In addition to obtaining fasting glucose levels at the site visits as outlined in the Schedule of 
Activities (Appendix 1), all patients enrolled in the study will be given a glucometer to 
monitor their daily fasting blood glucose (FBG) levels at home.  The level should be collected 
daily, predose on dosing days, and at approximately the same time each day. Before checking 
their blood glucose levels at site visits and at home, patients should fast overnight (nothing 
except water and/or medications after midnight or for a minimum of 8 hours before the 
assessment).   
On Cycle 1 Day 1, the patient will be provided an in-home glucometer.  Patients will be 
trained on proper use of the glucometer and instructed to collect a daily FBG level every 
morning (prior to the morning sapanisertib dosing, if applicable), starting on Cycle 1 Day 2.  
Patients will be instructed to bring the glucometer with them to each study visit so that the 
data collected can be reviewed and recorded in the source documents.  Investigators will be 
responsible for reviewing the home glucose monitoring logs for hyperglycemia. 
The patient will be instructed to contact the site immediately if the value is abnormal (ie, 
fasting blood glucose ≥ 160 mg/dL or random blood glucose > 200 mg/dL) for further 
instructions on the management of their hyperglycemia. Hyperglycemia observed during 
home glucose monitoring should be confirmed at the study site. 
If no irregularities in the FBG level are observed during a minimum of 2 consecutive cycles, 
then the frequency of in-home FBG testing can be reduced to a minimum frequency of once 
weekly, depending on the investigator’s judgment.  Patients will continue to notify the 
investigator of FBG levels that exceed 160 mg/dL and, if blood glucose levels are not well 
controlled, or if the patient requires either oral hypoglycemic agents or insulin to control 
blood glucose levels, then the frequency of in-home testing of FBG levels will be reinstated 
to daily.  See also Section 6.4.1.  Patients experiencing hyperglycemia while on study therapy 
may require more frequent glucose monitoring (eg, BID, TID, QHS), which varies based on 
severity.  Please refer to Table 3 for specific management guidelines. 
8.4 
Electrocardiograms 
Patients should rest in the supine or semi-recumbent position for at least 5 minutes before the 
12-lead ECG recording is started.  ECG recordings are to be performed as single-tracing 
evaluations, and must be performed using a standard, high-quality, high-fidelity 
electrocardiograph machine equipped with computer-based interval measurements.  As 
detailed in Appendix 1, single-tracing ECGs are to be obtained during Screening as well as 
the following on-treatment time points: 
• C1D1:  2 hours (±30 minutes) post dose 
• C2D1:  2 hours (±30 minutes) post dose 
• C3D1:  4 hours (±30 minutes) post dose 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 61 of 103 
When performed, the ECG must be reviewed by a qualified physician (or qualified 
physician’s assistant or nurse practitioner) and any clinically important finding recorded on 
the appropriate eCRF.  ECG results will include heart rate, R-R interval (RR), PR interval, 
QRS interval, QT interval, and QTcF interval.  The corrected QT interval will be corrected 
for respiratory rate according to the following formula: 
Fridericia’s formula:  QTcF = QT/RR0.33 
ECGs demonstrating prolonged QTcF > 480 ms, or other clinically significant abnormalities, 
should be repeated for confirmation. ECGs must be obtained and reviewed at the time points 
outlined in Appendix 1. 
8.5 
Vital Signs Measurements and Physical Examinations 
Vital sign measurements will include height, weight, resting systolic and diastolic blood 
pressure, respiratory rate, heart rate, oxygen saturation (SpO2), and temperature.  Height will 
be measured only at screening. 
Complete physical examinations will be performed by a licensed physician (or physician’s 
assistant or nurse practitioner) at screening and the EOT visit.  Symptom-directed physical 
exams can be done on all other visits.  System examinations are only required as clinically 
indicated.  The complete physical examination may include dermatologic, cardiac, 
respiratory, lymphatic, gastrointestinal, musculoskeletal, and neurologic systems, and other 
systems if clinically indicated by symptoms.   
8.6 
ECOG Performance Status 
ECOG performance status assessments are required to assess patient functional status for 
study eligibility purposes (during screening within 10 days of randomization) and will be 
performed throughout the study according to the schedule of activities (Appendix 1).  Details 
of the assessment are shown in Appendix 3.   
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 62 of 103 
9 ASSESSMENT OF EFFICACY, SAFETY, PHARMACOKINETIC, AND OTHER 
ENDPOINTS 
Assessments for efficacy and safety will be based on 21-day cycles.  Patients will be closely 
monitored for safety and tolerability while on study treatment up to a defined follow-up 
period after the last study treatment dose is taken or administered (Appendix 1).  All 
assessments must be performed and documented for each patient.   
9.1 
Assessment of Efficacy 
9.1.1 Assessments for the Primary and Secondary Efficacy Endpoints 
The assessment for the primary and secondary efficacy endpoints will include tumor imaging 
and assessment of survival.   
9.1.1.1  Tumor Imaging 
The tumor imaging schedule should follow calendar days relative to C1D1 regardless of 
delays in cycle visits (eg, due to dosing modifications).  
Radiographic Tumor Assessments 
Radiographic tumor assessments will include chest, abdomen, and pelvis.  Diagnostic quality 
CT with IV contrast or MRI scans with intravenous (IV) contrast will be performed in all 
patients at screening (within 28 days prior to C1D1) and every 6 weeks (± 5 days) from 
C1D1 onwards.  Additional tumor evaluations may occur if clinically indicated.  
For patients deemed intolerant to IV CT contrast, a noncontrast CT of the chest may be 
obtained along with a contrast-enhanced MRI of the abdomen and pelvis.  For tumor and 
tissue resolution, a contract-enhanced MRI of the abdomen and pelvis is preferred over a 
noncontrast CT of the abdomen and pelvis.  
PET-CT:  The low dose or attenuation correction CT portion of a combined PET-CT is not 
acceptable for determining RECIST measurements.  However, if the CT performed as part of 
a PET-CT is of identical diagnostic quality to a diagnostic CT (and includes the use of 
contrast) then the CT portion of the PET-CT can be used for RECIST measurements and can 
be used interchangeably with conventional CT in accurately measuring cancer lesions over 
time.  Note, however, that the PET portion of the CT introduces additional data which may 
bias an investigator if it is not routinely or serially performed.   
Baseline brain imaging with contrast enhancement (eg, MRI) is encouraged for all patients at 
screening.  Additionally, patients with a history of brain metastases or symptoms suggestive 
of CNS metastasis must have contrast-enhanced brain imaging performed at screening. 
Repeat brain scans will be performed only if the screening brain scan was positive, or as 
clinically indicated.  To optimize the reproducibility and accuracy of the assessment of 
existing and new tumor burden, the same imaging modality and acquisition protocols used at 
screening should be employed for all subsequent tumor assessments.  Of note, for the 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 63 of 103 
purposes of assessing tumor imaging, the term “investigator” refers to the local investigator 
and/or the radiologic reviewer located at the site or at an offsite facility. 
Imaging should continue to be performed until progressive disease is identified by the 
investigator, the start of new nonstudy anticancer therapy, withdrawal of consent, or death, 
whichever occurs first.   
Assessment of Tumor Response and Disease Progression 
RECIST v1.1 (Appendix 2) will be the primary measure for assessment of tumor response 
and disease progression for efficacy endpoints. 
Patients who discontinue study drug for reasons other than progressive disease or death 
should be followed by imaging per protocol-defined schedule until progressive disease per 
RECIST v1.1, death, initiation of a new anticancer therapy, or withdrawal of consent for 
disease follow-up, whichever occurs first. 
 
 
 
 
 
 
 
9.2 
Assessment of Safety 
Assessments of safety will include AEs, clinical laboratory tests, ECGs, vital sign 
measurements, physical examinations, and ECOG status.  The reason for permanent 
treatment discontinuation will also be collected.  The procedures for the investigator 
assessment of AEs are presented in detail in Section 8.2.  The procedures for clinical 
laboratory safety tests, vital sign measurements, ECGs, physical examinations and ECOG 
status are presented in Section 8.3 through Section 8.6.   
9.3 
Assessment of Other Endpoints 
9.3.1 Assessment of Pharmacokinetics  
Sparse blood samples for PK analysis of sapanisertib will be collected at the time points 
specified in Table 8 and Appendix 1.   The dates and exact times of administration of 
sapanisertib before collection of the blood sample for PK analysis and the dates and exact 
times of the postdose PK sample collection will be recorded on the eCRF. 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 64 of 103 
Table 8:  Collection Schedule for Pharmacokinetic Assessment 
Study Day 
Plasma Sample Collection Timepoints 
Sample Amount 
Cycle 1 day 1 
Predose (within 1 hour before dosing) 
3 mL 
Cycle 2 day 1 
Predose and 2 hr postdose (±30 min) 
3 mL 
Cycle 3 day 1 
4 hr and 6 hr postdose (±30 min) 
3 mL 
Cycle 4 day 1 
1 hr and 3 hr postdose (±30 min) 
3 mL 
Cycle 5 day 1 
Predose and 2 hr postdose (±30 min) 
3 mL 
Cycle 6 day 1 
4 hr and 6 hr postdose (±30 min) 
3 mL 
 
The actual time of PK sample collection must be noted in the source documents.  On day 1 of 
cycles 1, 2, and 5 patients will have their predose sample drawn.  Patients must record the 
time they took their previous dose before day 1 of cycles 2 and 5 and these must be noted in 
the source documents and eCRFs.  Since fasting is required for certain laboratory 
assessments, sites may offer a light meal or request that patients bring a light meal to their 
visits to consume after laboratory assessments have been completed and before dosing.  After 
completion of the laboratory assessment blood draws, patients will begin consuming the meal 
approximately 30 minutes before sapanisertib dosing, after which they will take their 
regularly scheduled doses of sapanisertib.  PK blood draws will be taken relative to the study 
drug dosing regardless of fasting status.  In the event of a delay in dosing on scheduled 
collection days, samples should be collected at a later study visit.  If a patient has not taken 
sapanisertib for at least 3 consecutive days immediately prior to a visit with PK sampling, 
samples should be collected at a later study visit, provided that patient has taken at least 3 
consecutive days of sapanisertib. 
Additional information regarding PK assessments will be provided in the study laboratory 
manual. 
9.3.2 
Tumor Biopsies 
9.3.2.1 
Archival Tumor Specimen Measurements 
 
 
 
 
 
 
 
 
 
 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of F
ics: For non-commercial use only and subject to the applicable Terms of Use


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 65 of 103 
9.3.2.2 
Tumor Biopsies 
Fresh tumor biopsies are not required for study entry.  
9.3.2.3 
Analysis of ctDNA 
 
 
 
 
 
 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of Faeth Therapeutics: For non-commercial use only and subject to the ap
le Terms of Use


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 66 of 103 
10 STATISTICAL METHODS AND SAMPLE SIZE DETERMINATION 
10.1 
Statistical and Analytical Plans 
 
 
 
 
 
 
. 
 
 
 
 
 
. 
The primary efficacy endpoint will be the investigator-assessed overall response rate (ORR) 
as measured by RECIST v1.1.  The primary safety endpoint will be measured by the type, 
incidence, severity, seriousness, and study drug-relatedness of adverse events per CTCAE 
v5.0.  The secondary efficacy endpoints and remaining safety endpoints will also be 
considered in the overall evaluation. 
For Group B (NFE2L2-WT sqNSCLC) a Simon’s Two-Stage analysis of ORR will be 
employed to assist in deciding whether there is sufficient efficacy to continue this Group B to 
the full planned enrollment.  Details can be found in Section 10.5. 
10.2 
Analysis Populations 
The analysis populations for the study are as follows: 
10.2.1 
Response Evaluable Population  
The response-evaluable population includes all patients who receive at least 1 dose of 
sapanisertib and have measurable disease at baseline and least 1 post-baseline disease 
assessment.  The primary efficacy analysis of ORR will be conducted using response-
evaluable population. 
10.2.2 
Intent-to-Treat (ITT) Population  
The ITT population will comprise all randomized patients.  Patients in the ITT population 
will be analyzed for treatment efficacy according to the treatment group to which they are 
randomized, regardless of post-randomization protocol deviations, including no protocol 
treatment received. 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 67 of 103 
10.2.3 
Safety Population   
The safety population includes all patients who receive at least 1 dose of sapanisertib.  The 
safety population will be used for all baseline characteristics, safety analyses, and exposure 
analysis. 
10.3 
Efficacy Analyses 
10.3.1 Overall Response Rate  
Overall Response Rate (ORR) is measured by RECIST v1.1.  ORR is defined as the 
percentage of patients with complete response (CR) or partial response (PR) criteria as 
assessed by the investigator.  Confirmation of response is not required for the ORR, but will 
be analyzed as supportive data.  All tumor evaluations on study are included in the analysis 
unless they are performed after the patient has received a cancer treatment not allowed by 
protocol.  Descriptive statistics will be used to compare the dose/schedules. 
10.3.2 Duration of Response 
For patients achieving a PR or a CR, the DOR will be calculated as the time between the first 
documentation of a PR or a CR to the first documentation of progressive disease or death, 
whichever occurs first.  For patients achieving first a PR then a CR, the PR date will be the 
starting date for calculation of the duration of response (DOR).  For responders for whom a 
progressive disease has not been documented yet, the DOR will be censored at the date of the 
last evaluable radiographic disease assessment prior to the occurrence of any of the following 
scenarios: 
• 
Patient is alive and progression free at the time of analysis data cutoff. 
• 
Prior to documentation of disease progression the patient receives non-protocol 
anticancer therapy, or any other treatment that in the opinion of the investigator 
interferes with assessment of disease per RECIST v1.1. 
• 
Patient misses 2 consecutive scheduled radiographic disease assessments (including 
missing assessments, insufficient data for the assessments, and an overall response of 
non-evaluable) followed by RECIST progression at the next assessment. 
 
Conventions regarding censoring for DOR and PFS will be described in the study statistical 
analysis plan (SAP), as will the planned descriptive statistics comparing the treatment group 
through Kaplan-Meier and Cox regression statistical procedures. 
10.3.3 Progression Free Survival 
PFS is defined as the time from randomization to the first occurrence of disease progression 
as determined by the investigator using RECIST v1.1 or death from any cause, whichever 
occurs first.  If the disease progression assessment involves more than one date, the earliest 
date will be used as the event date.  
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 68 of 103 
For responders for whom progressive disease or death has not been documented at database 
lock, the duration of PFS will be censored at the date of the last evaluable radiographic 
disease assessment post-baseline, or lacking a post-baseline assessment using the date of the 
first study treatment, prior to the occurrence of any of the scenarios described for DOR. 
Descriptive statistics will be produced comparing the treatment groups through Kaplan-Meier 
and Cox regression statistical procedures. 
10.3.4 Overall Survival 
OS is defined as the time from randomization to death due to any cause.  For patients alive at 
the time of analysis, OS will be censored at the time when the patient is last known to be 
alive.  Analyses of OS will be the same as the analyses described for PFS.  Descriptive 
statistics will be produced comparing the treatment groups through Kaplan-Meier and Cox 
regression statistical procedures. 
10.4 
Safety Analyses 
Safety analyses will include all randomized patients who receive any study drug, with 
patients allocated to the treatment group associated with the regimen actually received.  
Safety will be assessed by the patient incidence and severity of AEs.  The analysis will be 
performed on the safety population as defined in Section 10.2. 
Study drug exposure status for each study drug, which include treatment duration, total dose 
received (mg), and number of cycles, will be summarized for each treatment group for the 
safety population.  
AE terms recorded on the eCRFs will be coded to preferred terms using the Medical 
Dictionary for Drug Regulatory Activities (MedDRA®).   
Verbatim descriptions of AEs will be mapped to MedDRA terms and graded according to the 
NCI CTCAE v5.0.  All AEs occurring during or after the first study drug dose will be 
summarized by treatment group and NCI CTCAE grade.  In addition, AEs and SAEs leading 
to study drug discontinuation, reduction, and interruption will be summarized.  Multiple 
occurrences of the same event will be counted once at the maximum severity.   
Laboratory data with values outside of the laboratory reference ranges will be identified.  In 
addition, selected laboratory data will be summarized by treatment group and grade. 
Changes in vital sign measurements will be summarized by treatment group and grade.  
Changes in ECG and ECOG status are described in Section 8.4 and Section 8.6, respectively. 
10.5 
Determination of Sample Size and Simon’s Two-Stage Design 
No formal sample size calculations were performed for Group A, and no formal comparison 
will be performed between the dose cohorts for the primary efficacy endpoint. An aggregate 
analysis of safety and efficacy (both within dose cohort and across pooled cohorts if 
appropriate) will be performed to determine the best dose/schedule to take forward.  An ORR 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 69 of 103 
of approximately 
, if accompanied by acceptable efficacy and safety profiles, would 
support the further study of a dose/schedule. However, efficacy measures other than ORR, 
including DoR and PFS, will also be factored into the decision to further evaluate a 
dose/schedule. 
For Group B only, both dose/schedule cohorts will follow a Simon-2-Stage optimal design to 
test the null hypothesis that the true response rate is 
  In the first stage, when 9 response 
evaluable patients are accumulated in a dosing/schedule cohort the Stage 1 analysis will be 
performed (Table 9).  For either or both cohorts, if there are 0 responses among the 9 
response evaluable patients, enrollment will cease in the respective cohort(s).   Otherwise, 8 
additional response evaluable patients will be accrued for a total of 17 in the respective 
cohort(s).  The null hypothesis will be rejected if 3 or more responses are observed in 17 
patients.  This design yields a type I error rate of 
 and power of 
 to reject the null 
hypothesis when the true response rate is 0.25.  However, if no objective responses are 
observed among the first 10 response-evaluable patients enrolled in Group B (for both 
dose/schedule cohorts combined), the Sponsor reserves the right to discontinue Group B 
enrollment. 
Table 9:  Statistical Power for the Simon’s Two-Stage Design for Overall Response in 
Group B Dose/Schedule Regimens 
Stage 2 N 
Stage 1 N 
Responses 
in Stage 1 
[1] 
Responses 
in Stage 2 
[1] 
Type 1 
Error 
Power 
Probability 
of early 
stopping 
 
 
 
 
 
 
 
[1] Indicates the maximum number of responses observed at each Stage that leads to accepting 
the null hypothesis.  
 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 70 of 103 
11 STUDY COMMITTEES AND COMMUNICATIONS 
11.1 
Independent Radiology Committee  
 
 
 
 
 
 
 
11.2 
Study Steering Committee 
The SSC will comprise a subset of investigators and Sponsor personnel involved in the study, 
or other external key opinion leaders.  The SSC will oversee the conduct and reporting of the 
study, ensuring expert clinical guidance and a high standard of scientific quality, and making 
any necessary modifications to the protocol.  The SSC charter will define the responsibilities 
of the committee. 
11.3 
Independent Data Monitoring Committee 
The study will not have an independent data monitoring committee. 
 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 71 of 103 
12 LABORATORY REQUIREMENTS 
All study-related laboratory and clinical data gathered in this protocol will be stored in a 
password-protected database.  All patient information will be handled using anonymous 
identifiers.  Linkage to patients’ study data is only possible after accessing a password-
protected database.  Access to the database is only available to individuals directly involved 
in the study. 
A written document containing the name, location, certification number, and date of 
certification of the laboratory to be used for laboratory assays and those of other facilities 
conducting tests must be submitted to the Sponsor prior to initiating the study.  This 
document should be returned along with the Form FDA 1572.  The Sponsor must be notified 
if the laboratory is changed or if any additional laboratory is to be used. 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 72 of 103 
13 INVESTIGATOR AND ADMINISTRATIVE REQUIREMENTS 
The investigator will permit study-related monitoring, audits, IRB/IEC review, and 
regulatory inspections by providing direct access to source data and documents. 
All study-related information will be recorded on source documents.  All required data will 
be recorded in the eCRFs.  All eCRF data must be submitted to the Sponsor throughout and 
at the end of the study. 
If an investigator retires, relocates, or otherwise withdraws from conducting the study, the 
investigator must notify the Sponsor to agree upon an acceptable storage solution.   
Before initiating the study, the investigator must provide copies of the following documents 
to the Sponsor: 
• 
Fully completed and signed Form FDA 1572. 
• 
Fully executed clinical trial agreement. 
• 
Current curriculum vitae (also applies to all sub-investigators listed on the 
Form FDA 1572). 
• 
Current medical license (online verification is also acceptable; also applies to all sub-
investigators listed on the Form FDA 1572). 
• 
Financial disclosure (also applies to all sub-investigators listed on the 
Form FDA 1572) 
• 
Signed protocol signature page 
• 
Signed acknowledgement of receipt of the current  Investigator Brochure 
• 
IRB approval letter for the protocol and informed consent including written assurance 
of continuing approval (at least annually).  A copy of the annual progress report 
submitted to the IRB/IEC must also be provided. 
• 
IRB-approved informed consent form. 
• 
Where applicable, a list of the IRB/IEC members or a Federal-Wide Assurance/ 
Department of Health and Human Services (FWA/DHHS) number 
• 
Additional documents as necessary per local requirements. 
If an investigator changes during the course of the study, the Sponsor and any local 
regulatory authorities, as applicable, must first approve the change of investigator and the 
new investigator must provide the Sponsor all of the documents listed above.   
The Sponsor personnel or representatives may visit the study site, if necessary, before 
initiation of the study to review information with study site personnel about protocol 
requirements pertaining to the study drug, CRFs, monitoring, SAE reporting, and other 
relevant information. 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 73 of 103 
13.1 
Ethics 
13.1.1 
Institutional Review Board 
Before initiating the study, the investigator will obtain confirmation from the IRB that the 
IRB is properly constituted and compliant with all requirements and local regulations.   
The investigator will provide the IRB with all appropriate material, such as the protocol, 
current Investigator Brochure, site-specific informed consent form, and other written 
information provided to the patients.  The study will not be initiated until the investigator 
obtains appropriate IRB approval in writing for the protocol and informed consent document, 
and copies are received by the Sponsor.   
IRB approval will be obtained for any substantial protocol amendments and informed 
consent revisions before implementing the changes.  The investigator will provide 
appropriate reports on the progress of the study to the IRB, per local requirements, and 
to the Sponsor or designee in accordance with applicable local regulations.   
13.1.2 
Ethical Conduct of the Study 
This study will be conducted in accordance with the protocol and with the following: 
• 
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines 
• 
Applicable International Council for Harmonisation (ICH) Good Clinical Practice (GCP) 
Guidelines 
• 
Applicable laws and regulations 
• 
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
documents (eg, advertisements) must be submitted to an IRB/IEC by the investigator and 
reviewed and approved by the IRB/IEC before the study is initiated. 
• 
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an 
immediate hazard to study participants. 
• 
Any deviations to this protocol associated with the COVID-19 pandemic should be 
reported identifying this association. 
• 
The investigator will be responsible for the following: 
– Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/IEC 
– Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
IRB/IEC procedures 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 74 of 103 
– Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local 
regulations 
This study will be conducted under the guiding principles of the World Medical Association 
Declaration of Helsinki, including current GCP according to ICH guidelines.  Specifically, 
this study is based on adequately performed laboratory and animal experimentation; the study 
will be conducted under a protocol reviewed and approved by an IRB; the study will be 
conducted by scientifically and medically qualified persons; the anticipated benefits of the 
study are in proportion to the risks; the rights and welfare of the patients will be respected; 
the physicians conducting the study do not find the hazards to outweigh the potential 
benefits; and each patient will provide written informed consent before any protocol-specific 
tests or evaluations are performed.   
13.1.3 
Patient Information and Informed Consent 
Patient personal health information that is accessed for this study will not be reused or 
disclosed to any other person or entity, or for other research. 
A properly executed, written informed consent, in compliance with the Declaration of 
Helsinki, ICH GCP, US Code of Federal Regulations (CFR) for Protection of Human 
Subjects (21 CFR 50.25[a,b], CFR 50.27, and CFR Part 56, Subpart A), and local 
regulations, will be obtained from each patient before entering the patient in the trial.  The 
investigator or designee will prepare the informed consent form and provide the documents 
to the Sponsor or designee for approval before submission to the IRB.  The Sponsor and the 
IRB must approve the documents before the investigator implements them.   
The investigator will provide copies of the signed informed consent form to each patient and 
will maintain the signed original document within the patient’s clinical record per local 
requirements.  The investigator will also fully document the informed consent process in the 
patient’s source documents.   
13.1.4 
Maintaining Patient Confidentiality 
All reports and patient samples will be identified only by a study ID number and year of birth 
in order to maintain patient confidentiality.  Additional patient confidentiality issues are 
addressed in the clinical trial agreement and in the informed consent form signed by each 
study participant.   
13.2 
Data Quality Control and Assurance 
The Sponsor or designee performs quality control and assurance checks on all clinical studies 
that it Sponsors.  Before enrolling any patients in this study, Sponsor personnel and the 
investigator review the protocol, the current Investigator Brochure, the eCRFs and 
instructions for their completion, the procedure for obtaining informed consent, and the 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 75 of 103 
procedure for reporting AEs and SAEs.  A qualified representative of the Sponsor will 
monitor the conduct of the study.  During these site visits, information recorded in the eCRFs 
is verified against source documents.  
The following policies will be implemented to assure integrity of the data: 
• 
All participant data relating to the study will be recorded on eCRF unless transmitted 
to the Sponsor or designee electronically (eg, laboratory data).  The investigator is 
responsible for verifying that data entries are accurate and correct by physically or 
electronically signing the eCRF. 
• 
The investigator must maintain accurate documentation (source data) that supports 
the information entered in the eCRF. 
• 
The investigator must permit study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents. 
• 
Monitoring details describing strategy (eg, risk-based initiatives in operations and 
quality such as Risk Management and Mitigation Strategies and Analytical Risk-
Based Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniques (central, remote, or on-site 
monitoring) are provided in the study Monitoring Plan. 
• 
The Sponsor or designee is responsible for the data management of this study 
including quality checking of the data. 
• 
The Sponsor assumes accountability for actions delegated to other individuals (eg, 
Contract Research Organizations). 
• 
Study monitors will perform ongoing source data verification to confirm that data 
entered into the eCRF by authorized site personnel are accurate, complete, and 
verifiable from source documents; that the safety and rights of participants are being 
protected; and that the study is being conducted in accordance with the currently 
approved protocol and any other study agreements, ICH GCP, and all applicable 
regulatory requirements. 
Records and documents, including signed ICFs, pertaining to the conduct of this study must 
be retained by the investigator for 2 years after the last marketing authorization for the study 
drug has been approved or the Sponsor has discontinued its research with respect to such 
drug.  No records may be destroyed during the retention period without the written approval 
of the Sponsor.  No records may be transferred to another location or party without written 
notification to the Sponsor. 
13.2.1 
Data Protection 
Each patient will be assigned a unique number and will keep this number for the duration of 
the study.  Patient numbers will not be reassigned or reused for any reason.  Patients should 
be identified to the Sponsor only by their assigned study number, year of birth, and sex.  The 
investigator must maintain a patient master log.  
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 76 of 103 
The patient must be informed that his/her personal study-related data will be used by the 
Sponsor in accordance with local data protection law.  The level of disclosure must also be 
explained to the participant. 
The patient must be informed that his/her medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by 
appropriate IRB/IEC members, and by inspectors from regulatory authorities. 
13.2.2 
Data Management 
Clinical data management will be performed by the Sponsor or designee according to 
procedures described in a comprehensive data management plan.  The data management plan 
will include procedures for processing the data from this study, and will describe the 
responsibilities of the Sponsor and designee when clinical data management is provided by 
an external vendor.  In particular, the data management plan will include a list of the standard 
operating procedures that apply to this study.   
AEs and medications will be coded using MedDRA and the World Health Organization Drug 
Dictionary (WHO-DD), respectively.  The dictionary versions will be documented in the data 
management plan or relevant document.   
13.2.3 
Case Report Forms 
The study will use an EDC system.  All eCRFs will be designed and provided electronically 
to the site by the Sponsor or designee and EDC system vendor.  All eCRFs are to be 
completed, reviewed, and approved by the investigator or sub-investigators listed on the 
Form FDA 1572 or other appropriate local health authority documents. 
13.2.4 
Study Monitoring and Audits 
During the study, the Sponsor study monitor, or designee, will visit the site regularly to check 
the completeness of subject records, accuracy of entries on the eCRFs, adherence to the 
protocol and to GCP, progress of enrollment, and also the ensure that study drug is stored, 
dispensed, and accounted for according to specifications.   
Representative of the Sponsor must be allowed to visit all study site locations periodically to 
assess the data quality and study integrity. 
The data will be checked for completeness and correctness in real-time online.  Data are 
checked as they are entered into the appropriate eCRF.  Off-line checks will also be run to 
assess the need for additional data review. 
The Sponsor or designee will monitor this study in accordance with current GCP guidelines.  
By signing this protocol, the investigator grants permission to the Sponsor or designee and 
appropriate regulatory authorities to conduct onsite monitoring of all appropriate study 
documentation.  To ensure the accuracy of data collected on the eCRFs, it is mandatory that 
Sponsor representatives (eg, study monitor) have direct access to original source documents 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 77 of 103 
(eg, paper or electronic patient records, patient charts, and laboratory reports) needed to 
verify the entries in the eCRFs.  During the review of these documents, the anonymity of the 
patient will be respected with strict adherence to professional standards of confidentiality.   
A study monitor will contact and visit the site regularly and will be allowed, on request at 
a mutually acceptable time, to inspect the various original medical records related to the 
study.  The study monitor will be responsible for inspecting the eCRFs at regular intervals 
throughout the study, to verify the adherence to the protocol and the completeness and 
correctness of all eCRF entries.  The investigator agrees to cooperate with the study monitor 
to ensure that any problems detected in the course of these monitoring visits are resolved.   
During the course of the study and after study completion, it is likely that one or more quality 
assurance audits will be undertaken by authorized Sponsor representatives.  The purpose of 
the audit is to ensure that the study is (or was) conducted and monitored in compliance with 
the protocol as well as recognized GCP guidelines and regulations.  These audits will also 
increase the likelihood that the study data and all other study documentation can withstand 
a regulatory authority inspection.  If such audits are to occur, they will be arranged for 
a reasonable and agreed upon time.  By signing this protocol, the investigator grants 
permission to the Sponsor or designee to conduct onsite audits of all appropriate facilities and 
study documentation.   
13.2.5 
Protocol Deviations 
The investigator should not deviate from the protocol, except where necessary to eliminate an 
immediate hazard to study patients.  Should other unexpected circumstances arise that will 
require deviation from protocol-specified procedures, the investigator should consult with the 
Sponsor or designee (and IRB or IEC, as required) to determine the appropriate course of 
action.  There will be no exemptions (a prospectively approved deviation) from the study-
related procedures per protocol. 
The site should document all protocol deviations in the patient’s source documents.  In the 
event of a significant deviation, the site should notify the Sponsor or its designee (and IRB or 
IEC, as required).  Significant deviations include, but are not limited to, those that involve 
fraud or misconduct, increase the health risk to the patient, or confound interpretation of 
primary study assessment.   
13.3 
Investigational Product Accountability 
The investigator must maintain accurate records (including dates, quantities, and bottle 
identification numbers) of all study drug supplies received.  All records must be made 
available to the Sponsor, authorized representatives, and appropriate regulatory agencies, 
upon request.   
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 78 of 103 
Current ICH GCP guidelines require the investigator to ensure that study drug deliveries 
from the Sponsor are received by a responsible person (eg, pharmacist), and the following: 
• 
That such deliveries are recorded, for example, on the Sponsor’s drug accountability 
log or other Sponsor-approved pharmacy log 
• 
That study drug is handled and stored safely and properly in accordance with the label 
and the study protocol 
• 
That study drug is only dispensed to study patients in accordance with the protocol 
• 
That any used or unused drug is returned by the patient at each required visit 
• 
That any unused study drug is returned to the Sponsor-designated facility or standard 
procedures for the alternative disposition of unused study drug are followed and only 
after approval by the Sponsor representative 
Drug inventory and accountability records for the study drugs will be kept by the 
investigator/pharmacist.  Study drug accountability throughout the study must be 
documented.  The following guidelines are therefore pertinent:   
• 
The investigator agrees not to supply study drug to any persons except the patients 
in this study.   
• 
The investigator/pharmacist will keep the study drugs in a pharmacy or other locked 
and secure storage facility under controlled storage conditions as required by the 
study drug label, accessible only to those authorized by the investigator to dispense 
these study drugs.   
• 
The investigator/pharmacist will maintain a study drug inventory.  The inventory will 
include details of material received and a clear record of when they were dispensed 
and to which patient.   
• 
The investigator/pharmacist agrees to conduct a final drug supply inventory and to 
record the results of this inventory on the drug accountability record at the conclusion 
or termination of this study.  It must be possible to reconcile delivery records with 
those of used and returned study drug.  Any discrepancies must be accounted for.  
Appropriate forms of deliveries and returns must be signed by the person responsible.   
• 
Used or unused study drug may be destroyed at the study site according to standard 
institutional procedures if the Sponsor agrees with the procedure, and after drug 
accountability has been conducted by the Sponsor or representative, unless otherwise 
approved.  A copy of the standard institutional procedure for destroying 
investigational drugs will be provided to the Sponsor or designee upon request for 
review and approval before the first onsite destruction.  Unused study drug not 
destroyed at the site must be returned to the Sponsor-designated facility at the end 
of the study or upon expiration.   
13.4 
Financial Disclosure 
Investigators and sub-investigators will provide the Sponsor with sufficient, accurate 
financial information as requested to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities.  
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 79 of 103 
Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study. 
13.5 
Compensation for Injury and Insurance 
In the event of a side effect or injury, appropriate medical care as determined by the 
investigator or designated alternate will be provided.   
If bodily injury is sustained, resulting directly from the use of the study drug or by required 
study procedures, the Sponsor will reimburse the study site for reasonable physician fees and 
medical expenses necessary for treatment of only the bodily injury that is not covered by the 
patient’s medical or hospital insurance, provided that the injury is the following: 
• 
Not caused by the patient’s pre-existing medical condition or underlying disease;  
• 
Not due to a negligent or wrongful act or omission by the study doctor and study 
staff; 
• 
Not caused by the study doctor or study staff’s failure to follow the study protocol, 
other written instructions provided by the Sponsor, applicable laws or regulations; 
• 
Not requiring treatment that would have occurred as standard care if the patient was 
not taking part in the study.   
No other compensation of any type will be provided by the Sponsor.  Financial 
compensation for lost wages, disability, or discomfort due to the study participation or 
procedures is not available. 
13.6 
Retention of Records 
The investigator shall retain and preserve one copy of all data generated in the course of the 
study, specifically including but not limited to those defined by GCP as essential, for 
whatever period is longer:   
• 
2 years after the last marketing authorization for the study drug has been approved or 
the Sponsor has discontinued its research with respect to such drug  
or  
• 
Such longer period as required by applicable global regulatory requirements.  At the 
end of such period, the investigator shall notify the Sponsor in writing of its intent to 
destroy all such material.  The Sponsor shall have 30 days to respond to the 
investigator’s notice, and the Sponsor shall have a further opportunity to retain such 
materials at the Sponsor’s expense.  
The investigator must make original study data (paper or electronic) accessible to the study 
monitor, other authorized Sponsor representatives, and regulatory agency inspectors 
(eg, US FDA) upon request.  A file for each patient must be maintained that includes the 
signed informed consent form and copies of all source documentation related to that patient.  
The investigator must ensure the reliability and availability of source documents from which 
the information in the eCRF was derived.   
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 80 of 103 
Patient identity information recorded will be maintained for at least 15 years on the patient 
confidentiality log or longer if required by local regulations.   
Study documentation includes all essential documents as defined in ICH E6 Guidelines for 
Good Clinical Practice.  The Sponsor or designee will notify the investigator when any 
records may be discarded, but investigators must comply with local regulations.   
13.6.1 
Quality Assurance Audits and Regulatory Agency Inspections 
The study site also may be subject to quality assurance audits by the Sponsor or designees.  
In this circumstance, the Sponsor-designated auditor will contact the site in advance to 
arrange an auditing visit.  The auditor may ask to visit the facilities where laboratory samples 
are collected, where the medication is stored and prepared, and any other facility used during 
the study.  In addition, there is the possibility that this study may be inspected by the US 
FDA.  If the study site is contacted for an inspection by a regulatory body, the Sponsor 
should be notified immediately.  The investigator and institution guarantee access for quality 
assurance auditors to all study documents as described in Section 14. 
13.7 
Study Suspension, Termination, and Completion 
The Sponsor reserves the right to terminate the study or any part of the study at any time for 
any reason.  When the Sponsor is aware of information on matters concerning the quality, 
efficacy, and safety of the study drugs, as well as other important information that may affect 
proper conduct of the clinical study, the Sponsor may terminate the study and send a written 
notice of the termination along with the reasons to the investigator.   
If an investigator suspends or terminates the study, the investigator will promptly inform the 
Sponsor and the IRB/IEC and provide a detailed written explanation.  The investigator will 
also return all containers, as well as any other study materials, to the Sponsor or designee, or 
will destroy the materials at the investigative site.  Upon study completion, the investigator 
will provide the Sponsor, IRB/IEC, and regulatory agency with final reports and summaries 
as required by regulations. 
The investigator may initiate study-site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study site by the Sponsor or investigator may include, but 
are not limited to the following: 
• 
Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines 
• 
Inadequate recruitment of participants by the investigator 
• 
Discontinuation of further study intervention development 
The study will be considered complete when all randomized patients complete study follow-
up. 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 81 of 103 
14 USE OF STUDY INFORMATION AND PUBLICATION 
The results of this study will be published or presented at scientific meetings in a timely, 
objective, and clinically meaningful manner that is consistent with good science, industry and 
regulator guidance, and the need to protect the intellectual property of Calithera (Sponsor), 
regardless of the outcome of the trial.  The data generated in this clinical trial are the 
exclusive property of the Sponsor and are confidential.  Written approval from the Sponsor is 
required prior to disclosing any information related to this clinical trial, and no publications 
initiated by investigators may be published until all protocol-defined primary and secondary 
endpoints are published in a manuscript.  Every attempt will be made to minimize the 
interval between the completion of data analysis and publication of the study results.  
Recommendations for the timing of presentation of trial endpoint data and the publication 
venues (congresses/journals) will be given by the Sponsor’s Publications Steering 
Committee.   
Each investigator agrees to submit all manuscripts or congress abstracts and 
posters/presentations to the Sponsors prior to submission.  This allows the Sponsors to 
protect proprietary information, provide comments based on information from other studies 
that may not yet be available to the investigator, and ensure scientific and clinical accuracy.  
The details of the processes of producing and reviewing reports, manuscripts, and 
presentations based on the data from this trial will be presented in the investigator’s clinical 
study agreement.   
In accord with standard editorial and ethical practice, the Sponsors will generally support 
publication of multicenter trials only in their entirety and not as individual center data.  In 
this case, a coordinating investigator and lead author will be designated by mutual 
agreement.   
Any formal publication of the study in which input of Sponsor personnel exceeded that of 
conventional monitoring will be considered as a joint publication by the investigator and the 
appropriate Sponsor personnel.  Authorship will be determined by mutual agreement and all 
authors must meet the criteria for authorship established by the International Committee of 
Medical Journal Editors (ICMJE) Uniform Requirements for Manuscripts or stricter local 
criteria (ICMJE, 2021).  The Sponsors do not compensate for authorship of a publication and 
all authors will be required to disclose, as part of the publication submission, any potential 
conflicts of interest, including pertinent financial or personal relationships with the Sponsors 
or related entities, including Sponsors of competing products that might be perceived to be 
a source of bias.  Authorship is decided on an individual basis and the Sponsor’s Publications 
Steering Committee and Sponsor representatives will mutually determine authors and their 
sequence on individual publications based on the relative contribution of each author to the 
study and/or publication.   
Investigators in this study agree to have their name listed as an investigator in any 
publication reporting results from this study, whether or not they are an author on the 
publication.   
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 82 of 103 
Professional medical writing support is permissible, and any writing support will be 
acknowledged in each applicable publication, explaining the role the professional writer had 
in the drafting of the publication.  Medical writing and publications support funded by the 
Sponsors on behalf of investigator authors will be considered as a transfer of value under the 
reporting requirements of the Patient Protection Affordable Care Act:  Physician Payment 
Sunshine Provision. Transfer of value will be allocated to authors following Sponsor 
guidelines. 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 85 of 103 
16 SPONSOR APPROVAL 
FINAL PROTOCOL APPROVAL SHEET 
A Randomized, Open-Label Phase 2 Study of the TORC 1/2 Inhibitor Sapanisertib in 
Relapsed/Refractory NFE2L2 (NRF2)-Mutated and Wild-Type (WT) Squamous Non-Small 
Cell Lung Cancer (sqNSCLC) 
CX-228-301 
 
 
<<See Electronic Signature>> 
 
 
 
 
 
 
 
 
Date 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 90 of 103 
 
APPENDIX 2: RESPONSE CRITERIA IN SOLID TUMORS, VERSION 1.1 (RECIST V1.1) 
Source: Eisenhauer 2009 (Refer to Section 15 of the protocol for full citation information) 
Measurability of Tumor at Baseline 
Definitions 
At baseline, tumor lesions will be categorized measurable or nonmeasurable as described in the 
sections below. 
Measurable Tumor Lesions 
Tumor lesions must be accurately measured in at least one dimension (longest diameter in the plane 
of measurement is to be recorded) with a minimum size including the following:   
• 
10 mm by CT scan (CT scan slice thickness no greater than 5 mm) 
• 
10 mm by caliper measurement (lesions which cannot be accurately measured with calipers 
should be recorded as non-measurable) 
• 
20 mm by chest X-ray 
Malignant lymph nodes:  To be considered pathologically enlarged and measurable, a lymph node 
must be  15 mm in short axis when assessed by CT scan (CT scan slice thickness recommended to 
be no greater than 5 mm).  At baseline and in follow-up, only the short axis will be measured and 
followed.  Information on lymph node measurement is provided below under “Baseline 
Documentation of Target and Nontarget Lesions.” 
Nonmeasurable Tumor Lesions 
Nonmeasurable tumor lesions encompass small lesions (longest diameter < 10 mm or pathologic 
lymph nodes with  10 to < 15 mm short axis) as well as truly nonmeasurable lesions.  Lesions 
considered truly nonmeasurable include the following:  leptomeningeal disease, ascites, pleural or 
pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, 
peritoneal spread, abdominal masses/abdominal organomegaly identified by physical exam that is not 
measurable by reproducible imaging techniques. 
Special Considerations Regarding Lesion Measurability 
Bone lesions, cystic lesions, and lesions previously treated with local therapy require additional 
considerations for lesion measurements. 
Bone Lesions: 
• 
Bone scan, PET scan, or plain films are not considered adequate imaging techniques to 
measure bone lesions.  However, these techniques can be used to confirm the presence or 
disappearance of bone lesions.  
• 
Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components, 
that can be evaluated by cross-sectional imaging techniques such as CT or MRI can be 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 91 of 103 
 
considered as measurable lesions if the soft tissue component meets the definition of 
measurability described above. 
• 
Blastic bone lesions are nonmeasurable.  
Cystic Lesions: 
• 
Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor nonmeasurable) since they are, by 
definition, simple cysts. 
• 
“Cystic lesions” thought to represent cystic metastases can be considered as measurable 
lesions if they meet the definition of measurability described above.  However, if noncystic 
lesions are present in the same patient, these are preferred for selection as target lesions. 
Lesions With Prior Local Treatment: 
• 
Tumor lesions situated in a previously irradiated area, or in an area subjected to other 
loco-regional therapy will be considered nonmeasurable unless radiographic progression has 
been demonstrated subsequent to radiation therapy  
Specifications by Methods of Measurements 
Measurement of Lesions 
All measurements should be recorded in metric notation, using calipers if clinically assessed.  All 
baseline evaluations should be performed as close as possible to the treatment start and never more 
than 4 weeks before the beginning of the treatment. 
Method of Assessment 
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up.  Imaging based evaluation should 
always be done rather than clinical examination unless the lesion(s) being followed cannot be imaged, 
but are assessable by clinical exam. 
Clinical lesions:  Clinical lesions will only be considered measurable when they are superficial and 
 10 mm diameter as assessed using calipers (eg, skin nodules).  For the case of skin lesions, 
documentation by color photography including a ruler to estimate the size of the lesion is suggested.  
As noted above, when lesions can be evaluated by both clinical exam and imaging, imaging 
evaluation should be undertaken since it is more objective and may also be reviewed at the end of the 
study. 
Chest X-ray:  Chest CT is preferred over chest X-ray, particularly when progression is an important 
endpoint because CT is more sensitive than X-ray, particularly in identifying new lesions.  However, 
lesions on chest X-ray may be considered measurable if they are clearly defined and surrounded by 
aerated lung.  Still, noncontrast CT is preferred over chest X-ray. 
CT, MRI:  CT is the best currently available and reproducible method to measure lesions selected for 
response assessment.  This guideline has defined measurability of lesions on CT scan based on the 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 92 of 103 
 
assumption that CT slice thickness is 5 mm or less.  When CT scans have slice thickness greater than 
5 mm, the minimum size for a measurable lesion should be twice the slice thickness.  MRI is also 
acceptable in certain situations (eg, for body scans). 
If prior to enrollment it is known that a patient is not able to undergo CT scans with IV contrast due to 
allergy or renal insufficiency, the decision as to whether a noncontrast CT or MRI (with or without IV 
contrast) will be used to evaluate the patient at baseline and follow-up, should be guided by the 
anatomic location of the disease.  For patients who develop contraindications to contrast after baseline 
contrast CT is done, the decision as to whether noncontrast CT or MRI (enhanced or nonenhanced) 
will be performed, should also be based on the anatomic location of the disease and should be 
optimized to allow for comparison to the prior studies if possible.  Each case should be discussed with 
the radiologist to determine if substitution of these other approaches is possible and, if not, the 
patient should be considered not evaluable from that point forward. 
PET-CT:  The low dose or attenuation correction CT portion of a combined PET-CT is not 
acceptable for determining RECIST measurements.  However, if the CT performed as part of a 
PET-CT is of identical diagnostic quality to a diagnostic CT (and includes the use of contrast) then 
the CT portion of the PET-CT can be used for RECIST measurements and can be used 
interchangeably with conventional CT in accurately measuring cancer lesions over time.  Note, 
however, that the PET portion of the CT introduces additional data which may bias an investigator if 
it is not routinely or serially performed.   
Ultrasound:  Ultrasound is not useful in assessment of lesion size and should not be used as a method 
of measurement.  Ultrasound examinations cannot be reproduced in their entirety for independent 
review at a later date and, because they are operator dependent, it cannot be guaranteed that the same 
technique and measurements will be taken from one assessment to the next.  If new lesions are 
identified by ultrasound in the course of the study, confirmation by CT or MRI is advised.  If there is 
concern about radiation exposure at CT, MRI may be used instead of CT in selected instances. 
Endoscopy, laparoscopy:  The utilization of these techniques for objective tumor evaluation is not 
advised.  However, they can be useful to confirm complete pathologic response when biopsies are 
obtained or to determine relapse in trials where recurrence following complete response or surgical 
resection is an endpoint. 
Cytology, histology:  These techniques can be used to differentiate between PR and CR in rare cases 
if required by protocol (for example, residual lesions in tumor types such as germ cell tumors, where 
known residual benign tumors can remain).  When effusions are known to be a potential adverse 
effect of treatment (eg, with certain taxane compounds or angiogenesis inhibitors), the cytologic 
confirmation of the neoplastic origin of any effusion that appears or worsens during treatment can be 
considered if the measurable tumor has met criteria for response or stable disease in order to 
differentiate between response (or stable disease) and progressive disease. 
Tumor Response Evaluation 
Assessment of Overall Tumor Burden and Measurable Disease 
To assess objective response or future progression, it is necessary to estimate the overall tumor 
burden at baseline and use this as a comparator for subsequent measurements.  Only patients with 
measurable disease at baseline should be included in protocols where objective tumor response is the 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 93 of 103 
 
primary endpoint.  Measurable disease is defined by the presence of at least one measurable lesion.  
In studies where the primary endpoint is tumor progression (either time to progression or proportion 
with progression at a fixed date), the protocol must specify if entry is restricted to those with 
measurable disease or whether patients having non-measurable disease only are also eligible.  
Baseline Documentation of “Target” and “Nontarget” Lesions 
When more than one measurable lesion is present at baseline, all lesions up to a maximum of 
5 lesions total (and a maximum of 2 lesions per organ) representative of all involved organs should 
be identified as target lesions and will be recorded and measured at baseline.  For the purpose of 
target lesion identification, lymph nodes are considered as a single organ even though individual 
nodes may have different anatomic locations. 
In instances where patients have only 1 or 2 organ sites involved, a maximum of 2 (1 site) and 
4 lesions (2 sites), respectively, will be recorded.  Other lesions in that organ will be recorded as 
nonmeasurable lesions (even if size is greater than 10 mm by CT scan). 
Target lesions should be selected on the basis of their size (lesions with the longest diameter), be 
representative of all involved organs, but in addition should be those that lend themselves to 
reproducible repeated measurements.  On occasion, the largest lesion may not lend itself to 
reproducible measurement.  In this circumstance, the next largest lesion that can be measured 
reproducibly should be selected. 
Lymph nodes merit special mention because they are normal anatomic structures that may be visible 
by imaging, even if not involved by tumor.  Pathologic nodes, which are defined as measurable and 
may be identified as target lesions, must meet the criterion of a short axis of ≥ 15 mm by CT scan.  
Only the short axis of these nodes will contribute to the baseline sum.  The short axis of the node is 
the diameter normally used by radiologists to judge if a node is involved by solid tumor.  Nodal size 
is normally reported as two dimensions in the plane in which the image is obtained (for CT scan this 
is almost always the axial plane; for MRI the plane of acquisition may be axial, sagittal or coronal).  
The smaller of these measures is the short axis.  For example, an abdominal node which is reported as 
being 20 mm × 30 mm has a short axis of 20 mm and qualifies as a malignant, measurable node.  In 
this example, 20 mm should be recorded as the node measurement.  All other pathologic nodes (those 
with short axis  10 mm, but < 15 mm) should be considered nontarget lesions.  Nodes that have a 
short axis < 10 mm are considered nonpathological and should not be recorded or followed. 
A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters.  If lymph nodes are to be 
included in the sum, then as noted above, only the short axis is added into the sum.  The baseline sum 
diameters will be used as reference to further characterize any objective tumor regression in the 
measurable dimension of the disease. 
All other lesions (or sites of disease) including pathologic lymph nodes should be identified as 
nontarget lesions and should also be recorded at baseline.  Measurements are not required and these 
lesions should be followed as “present,” “absent,” “normal” (for nodal lesions < 10 mm along short 
axis), “increased,” or in rare cases “unequivocal progression.”  In addition, multiple nontarget lesions 
involving the same organ as a single item may be recorded on the eCRF (eg, “multiple enlarged 
pelvic lymph nodes” or “multiple liver metastases”). 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 95 of 103 
 
This default value is derived from the 5 mm CT slice thickness (but should not be changed with 
varying CT slice thickness).  The measurement of these lesions is potentially non-reproducible, 
therefore providing this default value will prevent false responses or progressions based upon 
measurement error. 
To reiterate:  If the radiologist is able to provide an actual measure, that should be recorded, 
even if it is below 5 mm and, in that case, BML should not be ticked.  (BML is equivalent to a 
less than sign <) 
Lesions that split or coalesce on treatment:  When non-nodal lesions “fragment,” the longest 
diameters of the fragmented portions should be added together to calculate the target lesion sum.  
Similarly, as lesions coalesce, a plane between them may be maintained that would aid in obtaining 
maximal diameter measurements of each individual lesion.  If the lesions have truly coalesced such 
that they are no longer separable, the vector of the longest diameter in this instance should be the 
maximal longest diameter for the “coalesced lesion.” 
Evaluation of Nontarget Lesions 
This section provides the definitions of the criteria used to determine the tumor response for the group 
of nontarget lesions.  While some nontarget lesions may actually be measurable, some may need not 
be measured and instead should be assessed only qualitatively at the time points specified in the 
protocol. 
Complete Response (CR):  Disappearance of all non-target lesions and normalization of tumor marker 
level.  All lymph nodes must be non-pathological in size (< 10 mm short axis). 
Non-CR/Non-PD:  Persistence of one or more non-target lesion(s) and/or maintenance of tumor 
marker level above the normal limits. 
Progressive Disease (PD):  Unequivocal progression of existing non-target lesions.  (Note:  the 
appearance of one or more new lesions is also considered progression). 
Special notes on assessment of progression of nontarget disease 
The concept of progression of nontarget disease requires additional explanation as follows: 
When the patient also has measurable disease:  In this setting, to achieve “unequivocal 
progression” on the basis of the nontarget disease, there must be an overall level of substantial 
worsening in non-target disease in a magnitude that, even in presence of stable disease or PR in 
target disease, the overall tumor burden has increased sufficiently to merit discontinuation of 
therapy.   A modest “increase” in the size of one or more nontarget lesions is usually not sufficient to 
qualify for unequivocal progression status.  The designation of overall progression solely on the basis 
of change in non-target disease in the face of stable disease or PR of target disease will therefore be 
extremely rare. 
New Lesions 
The appearance of new malignant lesions denotes disease progression; therefore, some comments on 
detection of new lesions are important.  There are no specific criteria for the identification of new 
radiographic lesions; however, the finding of a new lesion should be unequivocal (ie, not attributable 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 96 of 103 
 
to differences in scanning technique, change in imaging modality or findings thought to represent 
something other than tumor, for example, some “new” bone lesions may be simply healing or flare of 
pre-existing lesions).  This is particularly important when the patient’s baseline lesions show partial 
or complete response.  For example, necrosis of a liver lesion may be reported on a CT scan report as 
a “new” cystic lesion, which it is not.  Lymph nodes should not be recorded as new lesions unless 
they are at least > 10 mm along their short axis. 
A lesion identified on a follow-up study in an anatomic location that was not scanned at baseline is 
considered a new lesion and will indicate disease progression.  An example of this is the patient who 
has visceral disease at baseline and while on study has a brain CT or MRI ordered which reveals 
metastases.  The patient’s brain metastases are considered to be evidence of PD even if he/she did not 
have brain imaging at baseline. 
If a new lesion is equivocal, for example because of its small size, continued therapy and follow-up 
evaluation will clarify if it represents truly new disease.  If repeat scans confirm there is definitely a 
new lesion, then progression should be declared using the date of the initial scan. 
Evaluation of Best Overall Response 
The best overall response is the best response recorded from the start of study drug until the end of 
treatment taking into account any requirement for confirmation.  On occasion a response may not be 
documented until after the end of therapy so protocols should be clear if post-treatment assessments 
are to be considered in determination of best overall response.  Protocols must specify how any new 
therapy introduced before progression will affect best response designation.  The patient’s best 
overall response assignment will depend on the findings of both target and non-target disease and will 
also take into consideration the appearance of new lesions.  Furthermore, depending on the nature of 
the study and the protocol requirements, it may also require confirmatory measurement.  Specifically, 
in nonrandomized trials where response is the primary endpoint, confirmation of PR or CR is needed 
to deem either one the “best overall response.”  This is described further below. 
Timepoint Response 
It is assumed that at each protocol specified time point, a response assessment occurs.  Table A 
provides a summary of the overall response status calculation at each time point for patients who have 
measurable disease at baseline. 
When patients have nonmeasurable (therefore nontarget) disease only, Table B is to be used.  
Missing Assessments and Not-Evaluable Designation 
When no imaging/measurement is done at all at a particular timepoint, the patient is not evaluable at 
that timepoint.  If only a subset of lesion measurements are made at an assessment timepoint, it is 
usually considered not evaluable at that timepoint, unless a convincing argument can be made that the 
contribution of the individual missing lesion(s) would not change the assigned time point response.  
This assessment would be most likely to happen in the case of PD.  For example, if a patient had a 
baseline sum of 50 mm with 3 measured lesions and at follow-up only 2 lesions were assessed, but 
those 2 lesions gave a sum of 80 mm, the patient will have achieved PD status, regardless of the 
contribution of the missing lesion 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 97 of 103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
, 
 
 
 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 98 of 103 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Special Notes on Response Assessment 
When nodal disease is included in the sum of target lesions and the nodes decrease to “normal” size 
(< 10 mm), they may still have a measurement reported on scans.  This measurement should be 
recorded even though the nodes are normal in order not to overstate progression should it be based on 
increase in size of the nodes.  As noted earlier, patients with CR may not have a total sum of “zero” 
on the electronic case report form (eCRF). 
Patients with a global deterioration of health status requiring discontinuation of treatment without 
objective evidence of disease progression at that time should be reported as “symptomatic 
deterioration.”  Every effort should be made to document objective progression even after 
discontinuation of treatment.  Symptomatic deterioration is not a descriptor of an objective 
response, but a reason for stopping study therapy.  The objective response status of such patients is to 
be determined by evaluation of target and nontarget disease. 
In some circumstances it may be difficult to distinguish residual disease from normal tissue.  When 
the evaluation of complete response depends upon this determination, it is recommended that the 
residual lesion be investigated (fine needle aspirate/biopsy) before assigning a status of complete 
response.  FDG-PET may be used to upgrade a response to a CR in a manner similar to a biopsy in 
cases where a residual radiographic abnormality is thought to represent fibrosis or scarring.  The use 
of FDG-PET in this circumstance should be prospectively described in the protocol and supported by 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 99 of 103 
 
disease specific medical literature for the indication.  However, it must be acknowledged that both 
approaches may lead to false positive CR due to limitations of FDG-PET and biopsy 
resolution/sensitivity. 
For equivocal findings of progression (eg, very small and uncertain new lesions; cystic changes or 
necrosis in existing lesions), treatment may continue until the next scheduled assessment.  If at the 
next scheduled assessment, progression is confirmed, the date of progression should be the earlier 
date when progression was suspected. 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 100 of 103 
 
APPENDIX 3: ECOG SCALE FOR PERFORMANCE STATUS 
Grade 
Description 
0 
Normal activity. Fully active, able to carry on all predisease performance without restriction. 
1 
Symptoms but ambulatory. Restricted in physically strenuous activity, but ambulatory and 
able to carry out work of a light or sedentary nature (eg, light housework, office work). 
2 
In bed <50% of the time. Ambulatory and capable of all self-care, but unable to carry out any 
work activities. Up and about more than 50% of waking hours. 
3 
In bed >50% of the time. Capable of only limited self-care, confined to bed or chair more than 
50% of waking hours. 
4 
100% bedridden. Completely disabled. Cannot carry on any self-care. Totally confined to bed 
or chair. 
5 
Dead 
 
 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 101 of 103 
 
APPENDIX 4: NEW YORK HEART ASSOCIATION CLASSIFICATION OF CARDIAC 
DISEASE 
 
Class 
Functional Capacity 
Objective Assessment 
I 
Patients with cardiac disease but without 
resulting limitations of physical activity. 
Ordinary physical activity does not cause undue 
fatigue, palpitation, dyspnea, or anginal pain. 
Patients with cardiac disease but without 
resulting limitations of physical activity. 
Ordinary physical activity does not cause 
undue fatigue, palpitation, dyspnea, or 
anginal pain. 
II 
Patients with cardiac disease resulting in slight 
limitation of physical activity. They are 
comfortable at rest. Ordinary physical activity 
results in fatigue, palpitation, dyspnea, or anginal 
pain. 
Objective evidence of minimal cardiovascular 
disease. 
III 
Patients with cardiac disease resulting in 
marked limitation of physical activity. They are 
comfortable at rest. Less than ordinary activity 
causes fatigue, palpitation, dyspnea, or anginal 
pain 
Objective evidence of moderately severe 
cardiovascular disease. 
 
IV 
Patients with cardiac disease resulting in inability 
to carry on any physical activity without 
discomfort. Symptoms of heart failure or the 
anginal syndrome may be present even at rest. If 
any physical activity is undertaken, discomfort is 
increased. 
 
Objective evidence of severe cardiovascular 
disease. 
 
Source: The Criteria Committee of New York Heart Association, 1994 Nomenclature and Criteria for 
Diagnosis of Diseases of the Heart and Great Vessels. Ninth Ed. Boston, MA: Little, Brown & Co; 1994:253-
256. 
CX-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Calithera Biosciences, Inc. 
 Protocol CX-228-301 
04 Feb 2022 – Amendment 2, v3.0 
Confidential 
Page 102 of 103 
APPENDIX 5: DEFINITION OF ELIGIBLE MUTATIONS FOR ENROLLMENT 
-228-301 Protocol Amendment 04Feb2022 | eTMF Version 1.0 | VV-TMF-110817
Property of Faeth Therapeutics: For non-comme cial se nly nd subject o the applicable Terms of Use